



0001025307



000001025307

ΕΚΠΑ

Α. Π.: 38317

Ημ.: 25/04/2023

ΑΔΑ: ΨΒΦ346ΨΖ2Ν-8ΥΘ

ΑΙΤΗΣΗ

ΕΠΩΝΥΜΟ: ΒΑΣΙΛΕΙΟΥ
 ΟΝΟΜΑ: ΒΑΣΙΛΕΙΟΣ
 ΠΑΤΡΩΝΥΜΟ: ΚΩΝΣΤΑΝΤΙΝΟΣ
 ΗΜΕΡ.ΓΕΝΝΗΣΗΣ: 10 Μαρτίου 1962
 ΙΔΙΟΤΗΤΑ: Καθηγητής (YALE)
 Α.Δ.Τ./Αρ. Διαβατηρίου: USA 565790183
 E-mail: Vasilis.Vasilioi@Yale.edu

Θέμα: Υποψηφιότητα για τη θέση εξωτερικού μέλους του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών

Τόπος/Ημερομηνία:
New Haven 21/4/2023
CT, USA

Συνημμένα:

- α) Αντίγραφο Δελτίου Αστυνομικής Ταυτότητας ή Αντίγραφο Διαβατηρίου.
- β) Πλήρες βιογραφικό σημείωμα.
- γ) Οποιαδήποτε έγγραφα ή στοιχεία κρίνει ο/η υποψήφιος/α ότι θα υποστηρίξει την υποψηφιότητά του/ης (προαιρετικό).
- δ) Επιστολή εκδήλωσης ενδιαφέροντος για τη θέση του εξωτερικού μέλους.

ΠΡΟΣ

ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ
ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ

Με την παρούσα αίτηση:

α) υποβάλλω υποψηφιότητα για τη θέση εξωτερικού μέλους του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών σύμφωνα με την ισχύουσα νομοθεσία στο πλαίσιο της με αριθμ. πρωτ. 17890/28-2-2023, διεθνούς πρόσκλησης για την ανάδειξη των εξωτερικών μελών του Συμβουλίου Διοίκησης του Ιδρύματος,

β) αποδέχομαι τους όρους συμμετοχής στην παρούσα και δηλώνω ότι γνωρίζω τις υποχρεώσεις που απορρέουν από την ιδιότητα του εξωτερικού μέλους σε περίπτωση εκλογής μου, καθώς και τις αρμοδιότητες που ασκεί το Συμβούλιο Διοίκησης του Ε.Κ.Π.Α. σύμφωνα με το άρθρο 14 του ν. 4957/2022,

γ) δηλώνω ότι συναινώ στη συλλογή και επεξεργασία των προσωπικών δεδομένων μου, όπως αυτά αναφέρονται στην παρούσα πρόταση και στα συνυποβαλλόμενα με αυτήν δικαιολογητικά αποκλειστικά για την αξιολόγηση της αίτησής μου στο πλαίσιο της διαδικασίας της παρούσας.

Ο Αιτών / Η Αιτούσα
 (ονοματεπώνυμο και ψηφιακή υπογραφή)

Vasilis Vasilioi

Yale SCHOOL OF PUBLIC HEALTH

VASILIS VASILIOU, PhD
Susan Dwight Bliss Professor of Epidemiology
Chair, Department of
Environmental Health Sciences
Professor, Ophthalmology and Visual Sciences

PO Box 208034
New Haven CT 06520-8034
T 203 737-8094
vasilis.vasilio@yale.edu
publichealth.yale.edu

courier
60 College Street
New Haven CT 06510

April 21, 2023

Επιστολή εκδήλωσης ενδιαφέροντος για τη θέση του εξωτερικού μέλους του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών

Δρ. Βασίλειος Βασιλείου

Διευθυντής Τμήματος Περιβαλλοντικών Επιστημών Υγείας, Σχολή Δημόσιας Υγείας, Πανεπιστήμιο Yale, ΗΠΑ

Ο Δρ. Βασιλείου έλαβε το πτυχίο του στη Χημεία από το Πανεπιστήμιο Ιωαννίνων (1983) όπου ολοκλήρωσε και τη διδακτορική του διατριβή στη Βιοχημική Φαρμακολογία (1988). Κατόπιν τούτου, έλαβε την υποτροφία του ως Fogarty Fellow στις αλληλεπιδράσεις γονιδίων-περιβάλλοντος, στη μοριακή τοξικολογία και στη φαρμακογενετική στο Τμήμα Περιβαλλοντικής Υγείας του Κολλεγίου Ιατρικής του Πανεπιστημίου του Cincinnati (1991-1995). Εντάχθηκε ως επιστημονικός συνεργάτης στη Φαρμακευτική Σχολή του Πανεπιστημίου του Κολοράντο όπου και ανέλαβε Καθηγητής και Διευθυντής του Μεταπτυχιακού Προγράμματος Τοξικολογίας. Τον Ιούλιο του 2014, εντάχθηκε στη Σχολή Δημόσιας Υγείας του Πανεπιστημίου Yale και είναι Πρόεδρος του Τμήματος Περιβαλλοντικής Υγείας της ίδιας Σχολής.

Ο καθηγητής έχει καθιερώσει ένα διεθνώς αναγνωρισμένο ερευνητικό πρόγραμμα που χρηματοδοτείται συνεχώς από το 1997, από το NEI/NIH και το NIAAA/NIH και πρόσφατα από το NIEHS. Τα ερευνητικά του ενδιαφέροντα περιλαμβάνουν την αιτιολογία και τους μοριακούς μηχανισμούς των ανθρώπινων ασθενειών που προκαλούνται από το περιβάλλον, όπως η ηπατική νόσος, η παχυσαρκία και ο διαβήτης, ο καρκίνος και οι νευροεκφυλιστικές ασθένειες. Η έρευνά του επικεντρώνεται στα μέσα με τα οποία το εκθεσίωμα (συνολικές εκθέσεις σε όλη τη ζωή του οργανισμού), ο μεταβολισμός (συγκεκριμένα οι αφυδρογονάσες αλδεϋδης και το κυτόχρωμα P-450s) και τα αντιοξειδωτικά (γλουταθειόνη και καταλάση) συμβάλλουν στην ανθρώπινη υγεία και τις ασθένειες. Το εργαστήριό του, χρησιμοποιεί ολοκληρωμένες προσεγγίσεις με συστήματα τελευταίας τεχνολογίας που περιλαμβάνουν μεταβολομική, λιπιδομική, εκθεσιωμική, φασματομετρία μάζας απεικόνισης ιστών, μηχανική μάθηση, καθώς και ανθρώπινες κοόρτες και γενετικά τροποποιημένα μοντέλα ποντικών, προκειμένου να διαλευκανθούν μηχανισμοί και να ανακαλύφθουν βιοδείκτες και νέες καινοτόμες παρεμβάσεις για τις ανθρώπινες ασθένειες.

Ο Δρ. Βασιλείου είναι διευθυντής του ερευνητικού κέντρου P42 Yale Superfund που χρηματοδοτείται από το NIEHS και διευθυντής του R24-Resource Center for Mouse Models and Metabolomics Tools to Investigate Alcohol Metabolism and Tissue Injury που χρηματοδοτείται από το NIAAA.

Έχει δημοσιεύσει πάνω από 250 εργασίες και έχει επιμεληθεί τρία βιβλία για το αλκοόλ και τον καρκίνο. Είναι συντάκτης του Human Genomics και υπηρετεί στις συντακτικές επιτροπές αρκετών περιοδικών τοξικολογίας και

εικαστικών επιστημών. Είναι αφοσιωμένος στην εκπαίδευση της επόμενης γενιάς επιστημόνων. Στο Πανεπιστήμιο του Κολοράντο, διετέλεσε Διευθυντής του Προγράμματος Μεταπτυχιακών Σπουδών Περιβαλλοντικής και Μοριακής Τοξικολογίας για 15 χρόνια. Στο Yale ηγείται ενός Προγράμματος Εκπαίδευσης για μεταδιδακτορικούς ερευνητές, του Προγράμματος T32 Translational Alcohol Research Program (TARP) που χρηματοδοτείται από το NIAAA και του Εκπαιδευτικού Προγράμματος R25 Summer Research Experience in Environmental Health (SREEH) που χρηματοδοτείται από το NIHES και εισάγει προπτυχιακούς φοιτητές στην Έρευνα Περιβαλλοντικής Υγείας Κονέκτικατ (CT). Ο Δρ. Βασιλείου έχει εκπαιδεύσει, καθοδηγήσει και συμβουλευσει περισσότερους από 60 εκπαιδευόμενους, από μεταπτυχιακούς φοιτητές και υποψήφιους διδάκτορες έως μεταδιδακτορικούς υποτρόφους και κατώτερες σχολές.

Το Μάιο του 2022 αναγορεύθηκε (ομόφωνα) σε Επίτιμο Διδάκτορα του Τμήματος Χημείας του ΕΚΠΑ.

Τι μπορώ να προσφέρω ως εξωτερικό μέλος του Συμβουλίου Διοίκησης του Πανεπιστημίου Αθηνών;

Στα χρόνια της πολυετούς μου σταδιοδρομίας έφερα εις πέρας ένα διεθνώς αναγνωρισμένο ερευνητικό έργο, μέσω συνεχώς χρηματοδοτούμενων προγραμμάτων.

Γνωρίζοντας το υψηλό ακαδημαϊκό περιβάλλον της Ελλάδας, και ιδιαιτέρως του ΕΚΠΑ, θα επιχειρήσω να μεταφέρω την εμπειρία μου και τις προσλαμβάνουσες που αποκόμισα από τη θητεία μου από τα αμερικανικά πανεπιστήμια, στα ελληνικά δεδομένα. Η εμπειρία μου στο σύστημα Διοίκησης των Αμερικανικών Πανεπιστημίων θα μου επιτρέψει να προτείνω παρεμβάσεις που θα διευκολύνουν τις διοικητικές διαδικασίες στο ΕΚΠΑ. Η εκτεταμένη εμπειρία μου στη διεκδίκηση κονδυλίων για έρευνα σε ένα ιδιαίτερα ανταγωνιστικό περιβάλλον, θα μου επιτρέψει τη μεταφορά της τεχνογνωσίας μου στην υποστήριξη τέτοιων προσπαθειών και τη διασύνδεση των ερευνητών του ΕΚΠΑ με χρηματοδοτικές πηγές των ΗΠΑ. Η πρόσφατη συμμετοχή μου στο Pharos Summit και η εμπειρία μου στην ανάπτυξη συνεργασιών των ελληνικών πανεπιστημίων με το αμερικανικό οικοσύστημα ανώτατης εκπαίδευσης, θα μου επιτρέψει μέσω του Συμβουλίου Διοίκησης του ΕΚΠΑ να υποστηρίξω και να διευκολύνω την περαιτέρω διασύνδεση των τμημάτων και των σχολών του ΕΚΠΑ με ιδρύματα του εξωτερικού.

Είναι κάτι άλλωστε που έχω ήδη επιχειρήσει επιτυχώς με την πρόσφατη συνεργασία του Πανεπιστημίου Αθηνών με το Πανεπιστήμιο Yale των ΗΠΑ, μέσω της ίδρυσης μεταπτυχιακών προγραμμάτων σπουδών, διδακτορικής και μεταδιδακτορικής έρευνας αλλά και κοινών ερευνητικών προγραμμάτων για την προώθηση της περιβαλλοντικής επιστήμης και της δημόσιας υγείας.

Με εκτίμηση,

Vasilis Vasiliou

Δρ. Βασίλειος Βασιλείου

VASILIS VASILIOU, PhD
Curriculum Vitae

GENERAL/PERSONAL INFORMATION

Work Address: Department of Environmental Health Sciences,
Yale School of Public Health,
60 College Street, Rm. 511
PO Box 208034
New Haven, CT 06520-8034

Phone : (203) 737 8094
FAX: (203) 737 6023
E-mail: vasilis.vasiliou@yale.edu

EDUCATION

1979-1983 **BS, Chemistry**, School of Natural Sciences, University of Ioannina, Greece.
1983-1988 **PhD, Biochemistry**, Medical School, University of Ioannina, Greece.
1988-1990 **Postdoctoral training in Pharmacology**, University of Ioannina, Greece.
1991-1995 **Postdoctoral training in Molecular Toxicology & Pharmacogenetics**, University of Cincinnati, OH.

HONORARY DEGREES

2015 **Masters of Arts Privatim**, Yale University.
2022 **PhD, Chemistry**, National Kapodistrian University of Athens, Greece .

ACADEMIC APPOINTMENTS

2018- present **Susan Dwight Bliss Professor of Epidemiology**, Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut.
2014- present **Professor and Chair** (tenured), Department of Environmental Health Sciences, Yale School of Public Health, Yale School of Medicine, New Haven, Connecticut.
2007-2014 **Professor** (tenured), Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.
2001-2007 **Associate Professor**, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.
2001- 2014 **Director** of the Molecular Toxicology and Environmental Health Sciences Program, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.
2000- 2001 **Associate Director** of the Molecular Toxicology and Environmental Health Sciences Program, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.
1996-2001 **Assistant Professor**, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado.
1994-1995 **Research Associate**, Laboratory of Molecular Toxicology, Department of Environmental Health, University of Cincinnati Medical Center, Ohio, USA.

SECONDARY ACADEMIC APPOINTMENTS

- 2021-present **Professor Adjunct**, Department of Chemistry, National and Kapodistrian University of Athens, Greece.
- 2020- present **Professor** (secondary appointment), Yale School of the Environment, New Haven, Connecticut.
- 2014- present **Professor** (secondary appointment), Department of Ophthalmology & Visual Sciences, Yale Medical School, New Haven, Connecticut.
- 2008-2014 **Professor** (secondary appointment), Department of Ophthalmology, Medical School, University of Colorado Health Sciences Center, Denver, Colorado.

PROFESSIONAL EXPERIENCE

- 2017-2018 Member of the National Academies of Sciences, Engineering, and Medicine's Committee to Review Report on Long-Term Health Effects on Army Test Subjects.
- 2016 Discussant of EPA's Integrated Risk Information System (IRIS) Toxicological Review of Ethyl tert-Butyl Ether (ETBE).
- 2005-2006 **Guest Scientist**, Laboratory of Molecular and Developmental Biology, National Eye Institute, NIH, Bethesda, MD.
- 1991-1993 **Postdoctoral Fogarty Fellow**, Laboratory of Molecular Toxicology, Department of Environmental Health, University of Cincinnati Medical Center, Ohio, USA (Mentor: Dan W. Nebert).
- 1989-1990 **Service in Greek Army** as a Postdoctoral Research Fellow, Department of Pharmacology, Medical School, University of Ioannina, Greece (Mentor: Marios Marselos).
- 1984 **Visiting Fellow** (3 months), Departments of Physiology and Pharmacology & Toxicology, University of Kuopio, Finland (Mentors: Osmo Hanninen and Matti Lang).

TEACHING

Current (Yale School of Public Health)

Public Health Toxicology Course for MPH and PhD students (2016-) – 1 Yale credit (3 hrs and Course Director)

Past (University of Colorado School of Pharmacy, Graduate School and School of Medicine)

Principles of Drug Action (Pharmacogenetics) for Pharmacy and PharmD students – 3 credits (2hrs)

Toxicology for Pharmacy students (1997-2000) – 2 credits (Course Coordinator)

Clinical Sciences Foundation: Organ and Clinical Toxicology 2000-2014 (8 hrs and Course Director).

Graduate Toxicology Core Course I (2000-2014) – 3 credits (2 hrs)

Graduate Toxicology Core Course II (2000-2014) – 3 credit (4 hrs)

Graduate Drug Metabolism and Pharmacogenetics (1998-2014) – 3 credits (8 hrs plus coordination)

Instructional Methods 2 (P2) (Course Coordinator)

Graduate Course in Principles of Toxicology. Molecular and Biochemical Mechanisms (1993-2000)

Graduate course in Organ Systems Toxicity – 2 credits (6 hrs).

Graduate course in Occupational Toxicology – 2 credits (4 hrs)

Graduate Course in Cancer Biology – 2 credits (2hrs)

Graduate Course in Pharmacology – 3 credits (2 hrs)

ADVISING/MENTORING

MPH Students (at Yale School of Public Health)

Nathan Kloczko, Girish Motwani (2015-2016)
Lyndsay Gavin, Dan Huang, Alaina Perkins, Emma Ryan (2016-2017)
Nina Hatch, Hongwei Song (2017-2018)

PhD Students (Yale)

Brian Thompson (EHS) Awarded in 2021 (Advisor).
Yewei Wang (EHS) Awarded in 2022 (Advisor)
Emily Davidson (EHS) 2018-present (Advisor)
Xiuqui Ma (EHS) 2019-present (Advisor)

M.S. & PhD Students (University of Colorado)

Heather Marks-Hull (Toxicology), M.S. Awarded 1997 (Advisor).
Tia Estey (Pharm. Sciences), PhD. Awarded in 2007 (Co-Advisor).
Natalie Lassen (Toxicology Program), PhD Awarded in 2007 (Advisor).
Miriam Cantore (Pharmacology, Firenze, Italy), PhD Awarded in 2009 (Co-Advisor).
Satori Waddle (Toxicology Program), PhD Awarded in 2010 (Advisor).
William Black (Toxicology Program), PhD Awarded in 2011(Advisor).
Gurav Mehta (Toxicology Program), M.S. Awarded in 2011 (Advisor).
Brockner Chad (Toxicology Program), PhD Awarded in 2012 (Advisor).
Vindhya Koppaka (Toxicology Program), PhD Awarded in 2013 (Advisor).
Surendra Singh (Toxicology Program), PhD Awarded in May 2014 (Advisor).
Brian Jackson (Toxicology Program), PhD Awarded in 2015 (Advisor).
Claire Heit (Toxicology Program), PhD Awarded in 2016 (Advisor).
Andrew Monte (Medicine Program) PhD Awarded in 2018 (Co-Advisor).

Postdoctoral Fellows

Tomas Ziegler (1999-2000).
Jaqueline Wallisser (2000-2001).
Rizwan Manzer (2001-2002); Currently Research Associate at National Jewish Hospital, Denver, CO.
Manolis Merkouris, 2000-2003.
Aglaia Pappa (2000-2004); Currently Associate Professor, Department of Molecular Biology and Genetics Democritus University of Thrace, Greece (apappa@mbg.duth.gr).
Dimitrios Stagos (2007-2009); Currently Associate Professor, University of Thessaly, Greece. (stagkos@med.uth.gr).
Akiko Matsumoto (2009-2011); Currently Associate Professor, Saga University, Japan, matsumoa@cc.saga-u.ac.jp.
Hongbin Dong (2013- 2016).
Stephanie Marshall (2015-2017) (stephanie.m.marshall@gmail.com)
Surendra Singh (2015-2018).
Jeremy Koelmel (2019-2020) (jeremykoelmel@gmail.com)

Associate and Research Scientists

Ying Chen, Research Scientist, Yale School of Public Health (2014-present) (ying.chen@yale.edu)

Georgia Charkoftaki, Associate Research Scientist, Yale School of Public Health (2015-present)
(Georgia.Charkoftaki@yale.edu)

Zeljka Popovic. Postdoctoral fellow (2022-present) (zeljka.popovic@yale.edu)

Visiting Scholars

Salmaan H Inayat-Hussain, PhD, Environment, Social Performance, Product Stewardship and Toxicology, Group Health, Safety, Security and Environment, Petroliaam Nasional Berhad (PETRONAS), Kuala Lumpur, Malaysia, Fulbright Scholar, 2018.

Aikaterini Kandyliari, graduate student, Agricultural University of Athens, Fulbright Scholar, 2019.

Junior Faculty Development

Christina Aquilante, PharmD. Career development co-mentor on her K23 award (NIH/NIDDK, K23 DK073197, Genetic Predictors of Thiazolidinedione Response 07/01/06-06/30/11); currently Professor, Director of Pharmacogenomics for the Colorado Center for Personalized Medicine.

Andrew Monte, MD, PhD. Co-mentor on his K23 award (1K23GM110516, An Integrated Approach to Personalized Medicine, 2014-2018); currently Professor, Emergency Medicine-Medical Toxicology and Pharmacology, University of Colorado.

Ying Chen, PhD. Mentor (K01AA025093, Novel Redox-Associated Mechanisms Preventing Alcoholic Fatty Liver, 07/05/2016 – 06/30/2021); currently Research Scientist, Department of Environmental Health Sciences, Yale School of Public Health.

Natalie Neumann, MD Advisor. Department of Emergency Medicine, Yale School of Medicine. 2021-present.

Graduate Student Committees

Michail Panagiotidis (Toxicology), PhD in 2004 (Advisory Committee chair).

John Reichard (Toxicology), PhD in 2004 (Advisory Committee member).

Brante Sampey (Toxicology), PhD in 2005 (Advisory Committee member).

Kariya Chirag (Toxicology), PhD in 2007 (Advisory Committee chair).

Dan McShan (Bioinformatics), PhD in 2007 (Advisory Committee member).

Srirupa Roy (Toxicology), PhD in 2008 (Advisory Committee member).

Hongfei Zhou (Toxicology), PhD in 2010 (Advisory Committee member).

Becky Smathers (Toxicology), PhD in 2007 (Advisory Committee member).

Samiha Mateen (Toxicology), PhD In 2012 (Advisory Committee member).

James Galligan (Pharmacology) PhD in 2012 (Advisory Committee member).

Swetha Inturi (Toxicology), PhD in 2013 (Advisory Committee member).

Shrotriya, Sangeta (Toxicology), PhD in 2013 (Advisory Committee chair).

Derry Molly (Toxicology), PhD in 2013 (Advisory Committee chair).

Luis D Rita, Clinical Medicine Research, Imperial College London, (Advisory Committee member), 2022-present.

Alkistis Kevrekidou, School of Engineering, Department of Chemical Engineering, Aristotle University of Thessaloniki (Advisory Committee member), 2021-present.

Konstantina S Diamanti, Department of Chemistry, National and Kapodistrian University of Athens (Advisory Committee member) 2021-present.

Undergraduate researchers

Itay Melamed (MD student), 1997.
Scott Ostriker (4th year Pharmacy student), 1996-1997.
Lumunita Chang (4th year Pharmacy student), 1999.
Alison Veto (UCD), 2001-2002;
Qui Trong (UCD), 2002-2004.
Phil Weston (UC), 2004-2005.
Stella Polycarpou (DU), 2011-2012.
Chris Carpenter (CU) 2012-2014.
Melpomene Vasiliou (CU) 2013-2017.
Fay Walker (CU) 2014.

High School students

Chris Carpenter, 2009-2011.
Konstandinos Vasiliou, 2009-2012.
Ayathi Apostolopoulos, 2011.
Sarah Carpenter, 2011-2012.
Melpomene Vasiliou, 2011-2013.
Jared Alswang, 2012-2013.
Karan Agarwal, 2013.
Antonia Papadima, 2017.

ADMINISTRATIVE ACTIVITY AND UNIVERSITY SERVICE

Yale School of Public Health leadership

Chair, Department of Environmental Health Sciences (2014- present).
Director, Yale Superfund Research Center (funded by NIEHS) (2022-present).

University of Colorado AMC-School of Pharmacy leadership (1996-2014)

Director, Molecular Toxicology and Environmental Health Sciences Program (2001-2014)
Associate Director, Molecular Toxicology and Environmental Health Sciences Program (2000-2001).

Yale School of Public Health committees

Member, Appointments & Promotions Committee (2014-present).
Member, Executive Committee of the Climate Change and Health Initiative (2015-present).
Chair and Member, Stolwijk Fellowship Committee (2014-2018).
Member, Curriculum Revision Committee (2017)

Yale Comprehensive Cancer Center

Member, Shared Resource Oversight Committee (2015-present).
Member, Developmental Therapeutics (2014-present).

Yale Campus-Wide

Member, Scientific Advisory Board Yale Tobacco Centers on Regulatory Science (TCORS).

University of Colorado AMC-School of Pharmacy (1996-2014)

Member, DOPS Space Committee (1996-1999).

Member, Student Ethics and Conduct Committee (1999-2002).
Member, New Curriculum Design, Basic Sciences Course (1998).
Member, Development of the new curriculum for the Toxicology Graduate Program (2001).
Associate Director of the Toxicology Graduate Program (2000-2001).
Member, DOPS (SOP) APT Committee (2004-2005; 2007-2008).
Ad hoc member, DOCP (SOP) APT Committee (2006-2007).
Chair, Clinical/Translational Search Committee (2007).
Member, Dean's Review APT Committee (2008-2011).
Chair, DOPS (SOP) APT Committee (2011-2013).
Chair, Dean's Review APT Committee (2013-2014).
Associate Dean, Research Advisory Committee (2014).
UCAMC-Campus-wide (1996-2014)
Member, New Research Building Committee (1996).
Member, Resource Needs, Infrastructure, and Development Task Force (2007).
Member, Search Committee for Director of Research (Department of Ophthalmology (2007).
Member, Graduate School Dean Search Committee (2009-2010).
Member, Environmental Toxicologist Search Committee, Department of Biology, UCD (2009).

SPECIAL ASSIGNMENTS

Chair, DOPS Toxicology Program Seminar Series (1998-2003, 2005-2008).
Chair, Toxicology subcommittee for changes in the Graduate Curriculum (2000).

MEMBER OF PROFESSIONAL ORGANIZATIONS

The Society of Toxicology (SOT)
The Association for Research in Vision and Ophthalmology (ARVO)
The American Society of Human Genetics (ASHG)
The International Society for Developmental Origins of Health and Disease (DOHAD)

SERVICE IN PROFESSIONAL ORGANIZATIONS

Vice-President, MWSOT Regional Chapter (2007-2008).
President, MWSOT Regional Chapter (2008-2009).
Member, Career Resource and Development Committee of SOT (2009-2012).
Councilor, Mechanism Specialty Section of SOT (2010-2012).
Councilor, Ocular Toxicity Specialty Section of SOT (2010-2012).
Vice President-elect, Mechanism Specialty Section of SOT (2012-2013).
Vice President, Mechanism Specialty Section of SOT (2012-2013).
President, Mechanism Specialty Section of SOT (2013-2014).
Past President, Mechanism Specialty Section of SOT (2014-2015).

ADVISORY BOARDS

Member, Advisory Committee of the University Research Institute in Olive Groves and Olive Oils (2022-present)

Member, VRI Scientific Advisory Board (2022-present)

AWARDS, HONORS

1984	Research Scholarship, University of Kuopio, Finland.
1991-1993	International Research Fellowship, Fogarty International Center, NIH.
1998-present	IUPAC-IUBMB JBN ALDH Gene Nomenclature Committee.
2001	Teacher of the Year Award (selected by the Pharmacy First Professional Year Class).
2006	Travel Award ISBRA.
2011	Dean's Mentoring Award, University of Colorado AMC Graduate School.
2012	Travel Award ISBRA.
2013	John and Barbara Shell Prize for Excellence in Research and Graduate Education.
2014	Faculty Sponsor Award, University of Colorado AMC Graduate School.

CONFERENCE AND SYMPOSIUM ORGANIZATION

- 17th Annual Meeting of Mountain West Chapter of the Society of Toxicology, Breckenridge, Colorado, USA (September, 1999).
- 2nd International Alcohol and Cancer Conference, Breckenridge, CO, USA (May 11-15, 2013). (*Selected presentations from this meeting were published in Advances of Experimental Medicine and Biology 815: 1-436, 2015*).
- 3rd International Alcohol and Cancer Conference, Hersonissos Crete, Greece (May 29-June 2, 2015). (*Selected presentations from this meeting were published in Advances of Experimental Medicine and Biology 1032: 203-221, 2018*).
- Yale Symposium on Lifetime Exposures and Human Health: The Exposome, New Haven, CT, USA (April 19, 2017) (*A review was published in Human Genomics 11: 32, 2017*).
- 19th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism, Breckenridge, CO, USA. (July 2018).
- 1st International Symposium on Olive Oil and Health, New Haven, CT, USA. (October 3, 2018).
- 4th International Alcohol and Cancer Conference, Newport, RI, USA (April 14-18, 2019). (*Selected presentations from this meeting were published in a special issue of Chemico-Biological Interactions 331, 2021*).
- 2nd International Symposium on Olive Oil and Health, Delphi, Greece (December 1-4, 2019).
- 3rd International Symposium on Olive Oil and Health, Jaen, Spain (December 9-12, 2021).
- 4th International Symposium on Olive Oil and Health, Rome, Italy (September 15-18, 2022).
- Yale Symposium on Improving Reproducible Research Practices in Schools of Public Health, Yale School of Public Health, New Haven, CT, USA (April 16, 2018).
- Tissue Imaging Mass Spectrometry Symposium at Yale, Yale School of Public Health, New Haven, CT, USA (October 19, 2019). (*A review was published in Human Genomics 12:10, 2018*).
- Yale Imaging Mass Spectrometry and Omics Symposium, Yale School of Public Health, New Haven, CT, USA (November 22, 2019).
- Yale Symposium on Per- and Polyfluoroalkyl substances (PFAS): Challenges and Opportunities, Yale School of Public Health, New Haven, CT, USA (December 13, 2019). (*A review was published in Sci Total Environ. 778: 146192, 2021*).

- Yale Virtual Symposium on 1,4-Dioxane: Occurrence, Toxicity and Population Risk, Yale School of Public Health, New Haven, CT, USA (October 30, 2020). (*A special Issue of Current Opinion in Environmental Science & Health Special Issue has been devoted to this conference: Environmental Toxicology 2022: 1,4 Dioxane.*)

INVITED SPEAKING ENGAGEMENTS

- 6th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism, Dublin, Ireland (June 1992).
- 7th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism, New Palmerston, New Zealand (June 1994).
- International Workshop on Drug Metabolism and Toxicity in Balkan Countries, Ioannina, Greece (October 1995).
- 8th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism Enzymology and Molecular Biology of Carbonyl Metabolism, Deadwood, SD, USA (July 1996).
- The Midwest Cytochrome P-450 Symposium, Purdue, Indiana, USA (September 1997).
- 9th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism, Varallo Sesia, Italy (July 1998).
- 15th Annual Meeting of the Mountain West Chapter of the Society of Toxicology, Taos, NM, USA (October 1997).
- 17th Annual Meeting of Mountain West Chapter of the Society of Toxicology, Breckenridge, CO, USA (September 1999).
- 10th International Conference on the Enzymology and Molecular Biology of Carbonyl Metabolism, Taos, NM, USA (July 2000).
- 40th Annual Society of Toxicology Meeting, San Francisco, CA, USA (March 2001).
- 12th North American International Society for the Study of Xenobiotics (ISSX) Conference, Providence, RI (October 2003).
- 3rd Annual Meeting of the International Society of Pharmacogenomics, Santorini, Greece (October 2004).
- 22nd Annual Meeting of Mountain West Chapter of the Society of Toxicology, Park City, Utah, USA (September 2004).
- 3rd Annual Meeting of the International Society of Pharmacogenomics, Santorini, Greece (October 2004).
- 12th International Meeting on Enzymology and Molecular Biology of Carbonyl Metabolism, Burlington, Vermont, USA (July 2004).
- World Congress on Alcohol Research, International Society for Biomedical Research on Alcoholism (ISBRA) Sydney, Australia (September 2006).
- XVII International Society for Eye Research (ISER), Buenos Aires, Argentina (November 2006).
- Pacific Ocular Regenerative Biology Conference XII, Laguna Beach, CA, USA (September 16-19, 2007).
- Gordon Conference on "Drug Metabolism", Holderness School Holderness, NH, USA (July 2007).
- Research Society for Alcoholism/International Society for Biomedical Research on Alcoholism joint meeting, Washington, DC, USA (June 2008).

- Golden Helix Symposium, "Pharmacogenomics: Paving the path to personalized medicine", Athens, Greece (October 2009).
- Global Hellenic Medical & Biosciences Network (GHMBN), Lagonisi, Athens, Greece (September 2009).
- European Society for Biomedical Research on Alcoholism (ESBRA), Helsinki, Finland (June 2009).
- XIX Biennial Meeting of the International Society for Eye Research (ISER 2010), Montreal, Canada (July 2010).
- CLAO and Eye and Contact Lens Symposium on Ultraviolet Radiation and its Effects on the Human Eye, Las Vegas, NV, USA (September 2010),
- 2nd Asia Cornea Society Biennial Scientific Meeting, Osaka, Japan (December 2010).
- Satellite Meeting: Cornea Research Conference, Osaka, Japan (December 2010).
- 16th International Meeting on the Enzymology and Molecular Biology of Carbonyl Metabolism EnPloen, Germany (July 2012).
- XXth Biennial Meeting International Society for Eye Research (ISER), Berlin, Germany (July 2012).
- International Society for Biomedical Research on Alcoholism World Congress, Sapporo, Japan (September 2012).
- 18th North American International Society for the Study of Xenobiotics (ISSX) Conference, Dallas, TX, USA (October 2012).
- 5th Pan Arab Human Genetics Conference 2013, Dubai, United Arab Emirates, (November 2013).
- 17th International Conference on Enzymology and Molecular Biology of Carbonyl Metabolism, Poconos, PA, USA, (July 2014).
- 50th Congress of the European Societies of Toxicology (EUROTOX). Edinburgh, UK (September 2014).
- 10th International Symposium on Alcoholic and Pancreatic Diseases and Cirrhosis, Chile, (September 2015).
- 18th International Conference on Enzymology and Molecular Biology of Carbonyl Metabolism, Barcelona, Spain (July 2016).
- Biennial Meeting International Society for Eye Research (ISER) Congress, Tokyo, Japan (September 2016).
- Gordon Research Conference, Alcohol-Induced End Organ Diseases-"Metabolic Reprogramming and Molecular Mechanisms of Tissue Injury by Alcohol, Ventura, CA, USA (March 2017).
- Annual Research Society for Alcoholism Scientific Meeting, Denver, Colorado, USA (June 2017).
- Metabolomics in Translational Research', Waters Technology Summit, Georgetown University, Washington DC, MD, USA (July 2017).
- European Society for Biomedical Research on Alcoholism Congress, Herakleion, Greece (October 2017).
- European Society for Biomedical Research on Alcoholism Congress, Herakleion, Greece (October 2017).
- 100 Years of Ocular Sulfur Mustard: Models, Mechanisms and Therapeutics, (November 2017).
- 1st Zayed Center Genomic Medicine Workshop & the 20th Golden Helix Pharmacogenomics Day, College of Medicine and Health Sciences, Tawam Campus, Al-Ain, UAEU (February 2018).
- UAEU Research and Innovation Conference 2018, Future Engineering and Well-being of UAE,

- College, College of IT, Tawam Campus, Al-Ain, UAEU, (February 2018).
- 19th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism July, in Breckenridge, Colorado1, USA, (July 2018).
 - China-ASEAN Health Youth Forum, The 2nd China ASEAN Forum on Health Cooperation: Towards a Health Silk Road, Nanning, Guanxi, China, (September 2018).
 - 1st Interdisciplinary Conference “*Man and His Creations*”, Athens Call Athens, Online -Conference, “Promoting Ecosystem and Human Health Under Climate Change: An Integrated Framework for Sustainability Assessment of Olive Cultivation” (virtual) (October 2020).
 - *Plenary Lecture* Advanced Technologies for Drug Discovery: from Integrated Omics to Organ Chip, 11th National Conference of the Hellenic Society of Basic and Clinical Pharmacology, (virtual) (October 2020).
 - Biological Security, Public Health Hazard and Lessons Learned from the Pandemic, The International Exhibition of National Security and Resilience (ISNR), Abu Dhabi, United Arab Emirates, (October 2022).
 - *Lectio Magistralis*, Current Biological Safety and Security Threats, Workshop Cooperation in Preparedness and Response to Conventional and Non-conventional Emergencies, Tor Vergata University of Rome, Rome, Italy (September 12, 2022).
 - Use of Deep-learning to Evaluate the Beneficial Effects of Phytochemicals of the Olive Tree in Neurodegenerative Diseases, 1st International Olive Conference and Festival, Mytilini, Lesbos, Greece, Sept 23-25, 2022.
 - The Pontifical Academy of Sciences Conference on: The Art & Science of Olive Oil: Nutrition, Medicine and Planetary Health, Vatican, Italy (May 2022).
 - Cretan Lifestyle: Mediterranean Tradition & Modern Applications, Experiential Conference with American and Mediterranean Scholars, Creta Palace Resort, Rethymno, Crete, Greece, (November 2022).
 - Environmental Crisis: Consequences in Metabolic Balance and Human Health, Interdisciplinary School for Environmental Crisis: Science, Health, Economy, Social Sustainability, Thermae Sylla Spa & Wellness Hotel, Edipsos, Euboea, Greece, (December 2022).

INVITED SEMINARS

1. *Induction of Aldehyde Dehydrogenases by Chemical Carcinogens*. Department of Physiology, University of Kuopio, Kuopio, Finland (September 20, 1990).
2. *The mouse [Ah] Gene Battery: Positive and Negative Control of Gene Expression*. University of Ioannina Medical School, Ioannina, Greece (July 16, 1992).
3. *Organization and Characterization of the Murine Cytosolic TCDD-inducible Aldehyde Dehydrogenase Gene*. University of Ioannina Medical School, Ioannina, Greece (October 15, 1993).
4. *Murine Dioxin-Inducible Class 3 Aldehyde Dehydrogenase: Regulation of Gene Expression*. Environmental Toxicology Center, University of Wisconsin, Madison, WI, USA (March 31, 1994).
5. *Aldehyde Dehydrogenases and Environmental Oxidative Stress*. Center for Environmental Genetics, University of Cincinnati Medical Center, Cincinnati, OH, USA (April 11, 1995).
6. *Negative Regulation of the [Ah] Gene Battery: An Update*. Purdue University, West Lafayette, Indiana, IN, US (September 25-26, 1997).
7. *Polymorphisms of Human Alcohol and Aldehyde Dehydrogenases*. Toxicology Program, University of Cincinnati Medical Center, Cincinnati, Ohio, USA (March 1, 2000).

8. *Role of Aldehyde Dehydrogenases in Endogenous and Xenobiotic Metabolism*. Veterans Administration Medical Center, University of Southern California, Los Angeles, CA, USA (September 20, 2000).
9. *Mouse Aldh3a1: Tissue-specific and Inducible Gene Expression*. Laboratory of Molecular and Developmental Biology, National Eye Institute, NIH, Bethesda, Maryland, USA, (October 3, 2000)
10. *The Role of Aldehyde Dehydrogenases in Metabolism*. Laboratory of Metabolism, National Cancer Institute, NIH, Bethesda, Maryland, USA (October 5, 2000).
11. *Polymorphisms of the Human Aldehyde Dehydrogenases: Consequences for Drug Metabolism and Disease*. Toxicology Program, Colorado State University, Fort Collins, Colorado, USA (September 17, 2000).
12. *Polymorphisms of the Human Aldehyde Dehydrogenases: Consequences for Drug Metabolism and Disease*. Medical School University of Ioannina, Ioannina, Greece, (April 12, 2001).
13. *Multiple Protective Roles of the Corneal ALDH3A1 Against Oxidative Damage*. University of Texas Health Center at Tyler, Tyler, Texas, USA (August 6, 2002).
14. *Protective Role of Corneal Enzymes to Free Radical Oxidative Damage*. "Free Radicals in Medicine and Biology Seminar Course" (Colorado Oxygen Radical Society), Denver, CO, USA, (December 6, 2002).
15. *Aldehyde dehydrogenases protect against oxidative damage*. Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece (April 1, 2003).
16. *Aldehyde dehydrogenases protect against oxidative damage*. Department of Biology, Aristotelian University, Thessalonica (Greece, April 3, 2003).
17. *Protective Role of ALDH3A1 Against Oxidative Damage*. Department of Environmental Health, University of Cincinnati Medical Center, Cincinnati, OH, USA (May 28, 2003).
18. *Protective Role of Corneal ALDHs Against Oxidative Damage*. National Eye Institute, NIH, Bethesda, MD, USA (December 11, 2003).
19. *Multiple Roles of Aldehyde Dehydrogenase 3A1 (ALDH3A1) Gene*. National Eye Institute, NIH, Bethesda, MD, USA (June 2004).
20. *The Role of ALDHs in the Corneal Epithelium*, University of Washington, Seattle, WA, USA (February 2004).
21. *Protective Roles of Corneal ALDHs against Oxidative Damage*. University of Texas Medical Branch, Galveston, TX, USA, (December 2004).
22. *The Role of Aldehyde Dehydrogenases in Metabolism and Cellular Responses to Oxidative and Osmotic Stress*. Department of Experimental Medicine and Oncology, University of Turin, Italy (April 2005).
23. *Corneal Crystallins as a Cellular Response to Oxidative Stress*. Department of Pharmacology, University of Florence, Italy (April 2005).
24. *Cellular Responses to Oxidative and Osmotic Stress*. Department of Biochemistry and Molecular Biology, University of Louisville, KY, USA (May 2005).
25. *Corneal and Lens Crystallins and Cellular Responses to Oxidative Damage*. Department of Ophthalmology, Medical University of South Carolina, SC, USA (May 2005).
26. *Aldehyde Dehydrogenases and Oxidative Stress*. Laboratory of Kidney and Electrolyte Metabolism. NHLBI/NIH, Bethesda, MD, USA (November 2005).
27. *Role of Aldehyde Dehydrogenases in Metabolism and Cellular Response to Oxidative and Osmotic Stress*. NEI/NIH, Bethesda, MD, USA (December 2005).

28. Polymorphisms of Aldehyde Dehydrogenases: Consequences for Drug Metabolism and Disease, Department of Pharmacology and Physiology, The George Washington University Medical Center, Washington DC, USA (April 2006).
29. *Role of Aldehyde Dehydrogenases in Metabolism and Oxidative Stress*. NIAAA/NIH, Bethesda, MD, USA (April 2006).
30. *Diverse Functions of Corneal Crystallins*, Department of Ophthalmology. Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Seattle, USA (May 2006).
31. *Novel and Diverse Functions of Corneal ALDH3A1*. Department of Molecular Medicine, Harbor-UCLA Medical Center, Los Angeles, CA, USA (January 2007).
32. *Cataract Phenotype and Oxidative Damage in Aldh3a1- and Aldh1a1-null Mice*. Department of Ophthalmology, University of California Irvine, Los Angeles, CA, USA (January 2007).
33. *Role of ALDHs against Oxidative Damage*. Dipartimento Medicina ed Oncologia Sperimentale, University of Turin, Turin, Italy (June 2007).
34. *The Role of Corneal Crystallins in the Physiology and the Pathophysiology of the Eye*. Department of Ophthalmology, Medical University of South Carolina, SC, USA (March 2008).
35. *The Role of Aldehyde Dehydrogenases in Metabolism and Disease*. University of Kuopio, Kuopio, Finland (June 2009).
36. *The Role of Aldehyde Dehydrogenases in Metabolism and Disease with Emphasis to Cancer*. Institute of Occupational Health, Helsinki, Finland (June 2009).
37. *The Role of Aldehyde Dehydrogenases in Drug Metabolism*. Metabolic Disease and Cancer Stem Cells, UCLA, Los Angeles, CA, USA (April 2010).
38. Crystallins and Corneal Transparency. Distinguished Lecture Series, Cleveland Clinic, Cole Eye Institute, Cleveland, OH, USA (April 2010).
39. *Aldehyde Dehydrogenases: From Metabolic Disease to Cancer Stem Cells*. University of Vanderbilt, Nashville, TN, USA (November 2010).
40. *Aldehyde Dehydrogenases: From Metabolic Disease to Cancer Stem Cells*. Kitakyushu University, Japan (December 2010).
41. *Aldehyde Dehydrogenases: From Inherited Metabolic Diseases to Stem Cells and Cancer*. Grand Rounds in Clinical Genetics and Metabolism, Children's Hospital, University of Colorado Denver, Denver, CO, USA (January 2011).
42. Aldehyde Dehydrogenases and Cancer Stem Cells, Pathology Grand Rounds, University of Colorado Denver, USA (January 2011).
43. *Aldehyde Dehydrogenases: From Metabolic Disease to Cancer Stem Cells*. Lovelace Respiratory Research Institute, Albuquerque, NM, USA (February 2011).
44. *Aldehyde Dehydrogenases: From Corneal and Lens Crystallins to Cancer Stem Cells*. Jules Stein Eye Institute at UCLA, Los Angeles, CA, USA (June 2011).
45. *Systems Biology of GSH-Mediated Redox Sensing in Alcoholic Liver Disease*. National Institute on Alcohol Abuse and Alcoholism(NIAAA)/NIH, Maryland, USA (June 2012).
46. *Aldehyde Dehydrogenases: from Eye Crystallins to Metabolic Diseases and Cancer Stem Cells*. Saga University, Japan (September 2012).
47. *Aldehyde Dehydrogenases as Eye Crystallins, and their Role in Metabolic Diseases and Cancer Stem Cells*. The University of Texas Medical Branch at Galveston, Galveston, TX, USA (October 2012).
48. *Aldehyde Dehydrogenases as Potential Therapeutic Agents*. University of Colorado Cancer Center

- Seminar Series, Denver, CO, USA (October 2012).
49. *Aldehyde Dehydrogenases: From Metabolic Diseases and Cancer Stem Cells*. Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia (November 2013).
 50. *Aldehyde Dehydrogenases in Human Health and Disease*. Research Centre King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia (November 2013).
 51. *Aldehyde Dehydrogenases: From Crystallins to Stem Cells*. SUNY Downstate Medical Center, Brooklyn, NY, USA, February 2014.
 52. *Aldehyde Dehydrogenases In Cancer: Critical Players Rather Than Stem Cells Markers*. Center of Excellence in Environmental Toxicology (CEET) at the University of Pennsylvania, PA, USA (April 2015).
 53. *Interplay Between Alcohol and Glutathione in Obesity and Diabetes*, University of Louisville Diabetes and Obesity Center, Louisville, KY, USA (November 2015).
 54. *Alcohol and Antioxidants in Obesity and Diabetes*. University of North Carolina Nutrition Research Institute, Kannapolis, NC, USA (March 2016).
 55. *Department of Environmental Health Sciences at Yale School of Public Health: A Vision for the Future*. National Institutes of Environmental Health Sciences, NIH, Research Triangle Park (RTP), NC, USA (March 2016).
 56. *Toxicology Today*. Department of Biochemistry, University of Larissa, Larissa, Greece (March 2016).
 57. *Systems Approaches for Environmental Health Sciences Research*. Chinese National Institute for Environmental Health, Beijing, China (August 2016).
 58. *Metabolomics in Environmental Health Science Research*. Chinese Center for Disease Control (CDC), Beijing, China (August 2016).
 59. *Aldehyde Dehydrogenases in Cancer and Cancer Stem Cells*. Seminar Speaker, Pharmacology Seminar Series, Weill Cornell Medicine, New York, NY, USA (December 2016).
 60. *Aldehyde Dehydrogenases in Cancer Stem Cells: Molecular Mechanisms and Drug Development*. University of Connecticut, Farmington, CT, USA (May 2017).
 61. *Systems Approaches for Environmental Health Sciences in the 21st Century: Metabolomics and the Exposome*. Zhejiang University, Hangzhou, China, University (May 2017).
 62. *Aldehyde Dehydrogenases (ALDH) and Glutathione (GSH) are Key-players in Metabolic Disease and Cancer Stem Cells*, Department of Public Health, College of Political, Administrative and Communication Sciences Babes-Bolyai University, Cluj-Napoca, Romania (July 2017).
 63. *Systems Approaches for Environmental Health Sciences in the 21st Century*. Department of Public Health, College of Political, Administrative and Communication Sciences, Babes-Bolyai University, Cluj-Napoca, Romania (July 2017).
 64. *Genomics In Public Health Surveillance: From Deadly Viruses To Disease Susceptibility and Environmental Exposures*, Al Ain, United Arab Emirates University (UAEU) (February 2018).
 65. *Lipidomic and Metabolomic Analyses Reveal Lipid and Bile Acids Changes Indicative of Early Stage Alcohol Induced Liver Damage*, HOT Summer Seminar Series (virtual), Department of Physiology, Louisiana State University, New Orleans, USA (July 2020).
 66. *Genomics and Translational Epidemiology as Drivers for Public Health*, Public Health Webinars, Institute of Public Health, United Arab Emirates University (January 2022).

SOCIETY MEMBERSHIPS

Society of Toxicology (SOT) (1996-present).

Mountain West Chapter of Society of Toxicology (MW SOT) (1996-2014).
The Association for Research in Vision and Ophthalmology (ARVO) (1998-present).
Human Genome Organization (HUGO) (2010-present).
American Society of Human Genetics (2011-present).
International Society for Environmental Epidemiology (ISEE) (2017-present).
International Society for Biomedical Research on Alcoholism (ISBRA) (2000-present).
International Society for Eye Research (ISER) (2008-present).
European Society for Biomedical Research on Alcoholism (ESBRA) (2000-present).

GRANT/RESEARCH ACTIVITY

Current support

- Emerging Water Contaminants: Investigating and Mitigating Exposures and Health Risks, 1P42ES033815-01 (PI Vasilis Vasiliou), NIH/NIEHS, Total direct costs: \$4,733,336. 09/07/2022-06/30/2027.
- Understanding and Enhancing PFAS Phytoremediation Mechanisms Using Novel Nanomaterials, 5R01 ES032712-02 (MPI Vasilis Vasiliou-contact, Christy Haynes, Jason White) NIH/NIEHS, Total direct costs: \$682,111, 04/09/2021-01/31/2026.
- Genetic Causality of Alcohol Intake and Alcohol Use Disorder on Cancer Risk, 1R21CA252916-01A1 (PI: Hang Zhou), NIH/NIAAA, Total direct costs: \$257,125, 09/17/2021-08/31/2023
- Mouse Models and Metabolomics Tools to Investigate Alcohol Metabolism and Tissue Injury, 5R24AA022057-10 (PI Vasilis Vasiliou) NIH/NIAAA, Total direct costs: \$1,575,873, 09/20/2018-08/31/2023.
- Summer Research Experiences in Environmental Health (SREEH), 5R25ES029052-04 (MPI Vasilis Vasiliou, Yong Zhu), NIH/NIEHS, Total direct costs: \$490,775, 02/01/2019-01/31/2024.
- Identification of Biomarkers and Novel Pathways of Alcoholic Liver Disease by Leveraging Metabolomics, Tissue Imaging Mass Spectrometry, and Integrative Machine Learning, 5R21AA0284432-02 (PI Vasilis Vasiliou), NIH/NIAAA, Total direct costs: \$271,320, 04/10/2020-03/31/2023 (NCE).
- Translational Alcohol Research Program (TARP), 5T32AA028259-03 (MPI: Vasilis Vasiliou, Kelly Cosgrove), NIH/NIAAA, Total direct costs: \$2,064,960, 05/01/2020-04/30/2025.
- Yale Score on Sex Differences in Alcohol Use Disorder, 5U54AA027989-03 (PI: Sherry McKee), NIH/NIAAA, Total direct costs: \$5,000,000, 03/10/2020-02/28/2025.
- Catalyzing Bronchiolitis Therapeutics through Immune Response Profiling, 2019 Hartwell Individual Biomedical Research Award, Foundation Grant (PI: Richard Pierce), Total direct costs: \$300,000, 04/01/2020-03/31/2023.
- Boehringer Ingelheim International GmbH, Collaborative Research Agreement, (PI: Vasilis Vasiliou), Total direct costs: \$1,432,741, 05/20/2022-05/19/2025.

Past Support

- Novel Role of Corneal Crystallins as Modulators of Cell Growth and Transparency 5R01EY017963-08 (PI Vasilis Vasiliou), **Funded** NIH/NEI Total direct costs: \$883,187, 05/01/2017-04/30/2022.
- Identification of Biomarkers and Novel Pathways of Alcoholic Liver Disease by Leveraging Metabolomics, Tissue Imaging Mass Spectrometry, and Integrative Machine Learning ,

- 3R21AA0284432-02S1 (PI Vasilis Vasiliou), **Funded** NIH/NIAAA, Total direct costs: \$198,578, 09/05/2020-03/31/2022.
- Summer Research Experience in Environmental Health (SREEH), 3R25ES029052-02S1 (PI: Vasilis Vasiliou, Yong Zhu), **Funded** NIH/NIEHS, Total direct costs: \$98,155, 08/20/2020-01/31/2022.
 - Mouse Models and Metabolomics Tools to Investigate Alcohol Metabolism and Tissue Injury, 3R24 AA022057-08S1 (PI Vasilis Vasiliou) **Funded** NIH/NIAAA, Total direct costs: \$250,000 9/4/2019-8/31/2021.
 - The Role of ALDH1B1 in Ethanol Metabolism and Colon Cancer; 5R01AA021724-05 (PI Vasilis Vasiliou), **Funded** NIH/NIAAA, Total direct costs: \$1,328,578, 09/25/2014-08/31/2021 (NCE).
 - Novel Role of Corneal Crystallins as Modulators of Cell Growth and Transparency (Supplement), 3R01E017963-07S1, (PI Vasilis Vasiliou), **Funded** NIH/NEI, Total direct costs: \$100,000. 09/30/2018-04/30/2019
 - Mouse Models for Alcohol Metabolism and Tissue Injury; 3R24AA022057-06S1 (PI Vasilis Vasiliou), **Funded** NIH/NIAAA, Total direct costs: \$59,000. 7/6/2017-1/31/2019
 - Glutathione Monoesters to Counteract Ocular Chemical Injury (CounterACT) Exploratory/Development Projects in Translational Research, 1R21EY026776-01 (PI Vasilis Vasiliou), **Funded** NIH/NEI, Total direct costs: \$575,934, 9/30/15-9/29/18
 - Mouse Models for Alcohol Metabolism and Tissue Injury; 5R24AA022057-06 (PI Vasilis Vasiliou), **Funded** NIH/NIAAA, Total direct costs: \$902,839, 02/01/2013-09/19/2018.
 - 3rd International Alcohol and Cancer Conference. 1R13AA024046-01 (PI Vasilis Vasiliou), **Funded** NIH/NIAAA, Total direct costs: \$30,000, 04/01/2015-11/30/2017 (NCE).
 - Role and Molecular Mechanisms Corneal Aldehyde Dehydrogenase, 7R01EY11490-16 (PI Vasilis Vasiliou), **Funded** NIH/NEI, Total direct costs \$1,801,728; 7/1/09-6/30/2016 (NCE).
 - A Novel Aldehyde Dehydrogenase (ALDH16A1) in Gout; 5R21AR064137-02 (PI Vasilis Vasiliou), **Funded** NIH/NIAMS, Total direct costs: \$253,936; 09/16/2014-01/31/2017 (NCE).
 - Mouse Models for Alcohol Metabolism and Tissue Injury, 3R24 AA022057-03S1 (PI Vasilis Vasiliou), **Funded** NIH//NIAAA, Total direct costs \$93,418, 8/1/13-1/31/17
 - The role of GSH in cornea and lens development; 7R21EY021688-03, NIH/ NEI (PI Vasilis Vasiliou), **Funded** 07/01/2012-08/31/2015.
 - Biochemical, Structural and Polymorphic Characterization of Human ALDH1B1, 1F31AA020728-01, (NRSA fellowship for Brian Jackson; Role: **Mentor**) 07/01/2011-06/30/2015.
 - Aldehyde Dehydrogenases as Targets to Treat Acute Myeloid Leukemia (PI Vasilis Vasiliou), **Funded** Skaggs School of Pharmacy Colorado/University of Colorado. 7/1/11 – 6/30/2013.
 - Alcohol and Cancer Conference. 1R13AA021659-01, NIAAA/NIH (PI Vasilis Vasiliou), **Funded** 07/01/2012-08/30/2013
 - Role of ALDH7A1 in Ethanol-Induced Oxidative Damage; 1F31AA018248-01 (NRSA fellowship for Chad Brocker; **Role: Mentor**), **Funded**; \$29,417 per year, \$88,251 total; 09/30/2010 – 09/29/2013 (terminated due to graduation in May 2012).
 - The role of mitochondrial aldehyde dehydrogenases in ethanol metabolism and toxicity, NIH/NIAAA, 5R21AA017754-02 Vasiliou (PI, Vasilis Vasiliou); **Funded**; Direct cost \$275,000; 07/01/09-06/30/11.
 - Aldehyde Dehydrogenase 3B1: Characterization and Role in Oxidative Stress 1 F31 AA016875-

- 01 (Satori Marchitti Student, **Mentor** Vasilis Vasiliou), **Funded**; Direct Costs: \$82,500; 1/1/07-12/31/09.
- Molecular Mechanisms and Role of the Corneal Aldehyde dehydrogenase NIH/NEI, 3R01EY11490-09S1 ((P.I. Vasilis Vasiliou, **Funded**; \$78,950; 8/01/07 to 3/31/09.
 - Molecular Mechanisms and Role of the Corneal Aldehyde dehydrogenase NIH/NEI, 5R01EY11490-06. (P.I. Vasilis Vasiliou), **Funded**; \$1,250,000 (direct costs); 4/01/04 to 3/31/09.
 - Role of Lipid Aldehydes in Ethanol-Induced Liver Injury, NIH/NIAAA, 5R01AA09300-05. (Dennis R. Petersen P.I., Vasilis Vasiliou Co-PI), **Funded**; \$1,400,000 (direct costs), 04/01/01-03/31/06.
 - Genetic Models to Study Alcohol Toxicity. NIAAA 5R01AA11885-05 (P.I. Vasilis Vasiliou), **Funded** \$867,203 (direct costs), 1/1/99-12/31/04.
 - Role of Aldehyde Protein Adducts in CCl₄-Induced Liver toxicity. NIEHS 5R01ES09410-05, (Dennis R. Petersen P.I., Vasilis Vasiliou Co-PI), **Funded**; \$1,250,854 (direct costs), 9/15/00-9/15/05.
 - Role of CYP2E1 in Fetal Alcohol Syndrome, NIAAA, Predoctoral Fellowship for the student Susanne Williams, Mentor Vasilis Vasiliou, **Approved**; \$45,000; 8/1/98 to 7/30/01.
 - Molecular Mechanisms and Role of the Corneal Aldehyde dehydrogenase NIH/NEI, R29EY11490. (P.I. Vasilis Vasiliou) **Funded**; \$349,835 (direct costs); 506,097 (total costs), 1/12/97 to 30/11/2002.
 - Transgenic Mouse Models to Study the Role of Neurotensin Receptor in Ethanol Sensitivity, NIH/NIAA, Pilot project with the Alcohol Research Center. (Vasilis Vasiliou P.I.) **Funded**; \$50,000, 12/1/99 to 11/30/02.
 - Role of Lipid Aldehydes in Ethanol-Induced Liver Injury, NIH/NIAAA, R01 AA09300. (Dennis R. Petersen P.I., Vasilis Vasiliou Co-PI), **Funded**; \$859,283 (direct costs) 1,283,085 (total costs), 04/01/97-03/31/01.
 - Characterization of the ethanol metabolism pathways in Zebrafish. Department of Pharmaceutical Sciences Seed Grant. (Robert Tanguay & Vasilis Vasiliou) **Funded**; \$10,000; 7/1/00 to 7/1/01.
 - Pharmacogenetics of cyclophosphamide metabolism. Department of Pharmaceutical Sciences Seed Grant. (Mark Duncan, Daniel Gustafson, Peter Kazakoff, & Vasilis Vasiliou, PhD) **Funded**; \$10,000; 7/1/00 to 7/1/01
 - Role of Neurotensin Receptor in Ethanol Sensitivity, Department of Pharmaceutical Sciences Seed Grant. (P.I. Vasilis Vasiliou) **Funded**; \$10,000; 7/1/98 to 7/1/1999.
 - Transcriptional Regulation of Genes Involved in Human Disease. Department of Pharmaceutical Seed Grant, (P.I., Vasilis Vasiliou) **Funded**; 5,000; 4/1/97 to 4/28/98.
 - Transcriptional Activators of Oxidative Stress. Department of Pharmaceutical Sciences Seed Grant. (P.I. Vasilis Vasiliou) **Funded**; \$10,000; 7/1/96 to 7/1/1997.
 - Molecular Basis of Cyclophosphamide Resistance. Colorado Cancer Center Seed Grant. (P.I. Vasilis Vasiliou) **Funded**; \$10,000; 9/8/96 to 8/30/97.

PROFESSIONAL AND INSTITUTIONAL SERVICE

Editorial Boards:

- 2007-present The Ocular Surface
2013-present Expert Opinion on Drug Metabolism & Toxicology

Executive/Associate Editor:

- 2010-2016 Experimental Eye Research
2019-present Developmental Origins of Health and Disease
2018-present Frontiers in Artificial Intelligence

Editor-in-Chief:

- 2008- present Human Genomics

Journal reviewer

Alcohol & Alcoholism, Alcoholism Clinical & Experimental Research, American Journal of Pathology, Archives of Biochemistry and Biophysics, Biochemical Pharmacology, Biochemical Biophysical Acta, British Journal of Nutrition, British Journal of Pharmacology; Cancer Letters, Cancer Chemotherapy and Pharmacology, Carcinogenesis, Cellular and Molecular Life Sciences, Chemical Research in Toxicology, Chemico-Biological Interactions, Comparative Biochemistry and Physiology, Clinical Chemistry and Laboratory Medicine, DNA Sequence, Digestive Diseases and Sciences, Drug Metabolism and Disposition, Experimental Eye Research, Genomics, Endocrine Reviews, European, Free Radicals in Biology and Medicine, Journal of Pharmacology, Journal of Human Genetics, Investigative Ophthalmology and Visual Sciences, International Journal of Cancer, International Journal of Biological Macromolecules, Life Sciences, Molecular Pharmacology, Journal of Biological Chemistry, Pharmacogenetics & Genomics.

Granting Agency reviewer

- Greek Ministry of Research and Technology (2005 *ad hoc*).
NIH ZRG1 AED Study Section (2004-2005 *ad hoc*).
NIH ZRG1 AED Study Section (2005-2009 regular member).
NIH ZAA1 BB Study Section (2007- 2008 *ad hoc*).
NIH ZAA1 JJ (12) Study Section (2007 *ad hoc*).
NIH DPVS Study Section (March 2012 *ad hoc*)
NIH CBSS Study Section (February 2012 *ad hoc*)
NIH ZRG1 MOSS-S (04) (March 2012 *ad hoc*)
NIH AA-1 Study Section (2009-2011 regular member)
NIH AA-1 Study Section (2011-2013 chair; 2017 *ad hoc*)
NIH DPVS Study Section (2013-2019 *ad hoc*)
NIH ZEY1 VSN study section (05) (August 2014 *ad hoc*)
NIH ZAA1 Study Section (2006-present *ad hoc*)

Reviewer for Society of Toxicology, University of Colorado and Yale University

Specialist Advisor

- HUGO Gene Nomenclature Committee (<http://www.gene.ucl.ac.uk/nomenclature/advisors.html>)

PUBLICATIONS (h-index 69 as of March 2023)

Journals

1. **Vasiliou V**, Malamas M, Marselos M. The mechanism of alcohol intolerance produced by various therapeutic agents. **Acta Pharmacol et Toxicol** 58: 305-310, 1986. PMID: 2943133.
2. **Vasiliou V**, Marselos M. Tissue distribution of inducible aldehyde dehydrogenase activity in the rat after treatment with phenobarbital or methylcholanthrene. **Pharmacol & Toxicol** 64: 39-42,

1989. PMID: 2755909.
3. **Vasiliou V**, Marselos M. Changes in the inducibility of a hepatic aldehyde dehydrogenase by various effectors. **Arch Toxicol** 63: 221-225, 1989. PMID: 2764709.
 4. **Vasiliou V**, Torronen R, Malamas M, Marselos M. Inducibility of liver cytosolic aldehyde dehydrogenase activity in various animal species. **Comp Biochem & Physiol** 94C: 671-675, 1989. PMID: 2576795.
 5. Marselos M, **Vasiliou V**. Effects of various chemicals on the aldehyde dehydrogenase activity of the rat liver cytosol. **Chem Biol Interactions** 79: 79-89, 1991. PMID: 2060039.
 6. Marselos M, **Vasiliou V**, Malamas M, Alikaridis F, Kefalas T. Effects of cannabis and tobacco on the enzymes of alcohol metabolism in the rat. **Rev Environm Health** 9: 31-37, 1991. PMID: 1957048.
 7. **Vasiliou V**, Puga A, Nebert DW. Negative regulation of the murine cytosolic aldehyde dehydrogenase-3 (Aldh-3c) gene by functional CYP1A1 and CYP1A2 proteins. **Biochem Biophys Res Commun** 187: 413-419, 1992. PMID: 1520328.
 8. **Vasiliou V**, Puga A, Nebert DW. Mouse class 3 aldehyde dehydrogenases: positive and negative regulation of gene expression. **Adv Exp Med Biol** 328: 131-139, 1993. PMID: 84938
 9. Nebert DW, Puga A, **Vasiliou V**. Role of Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer and signal transduction. **Ann N Y Acad Sci** 658: 624-640, 1993. PMID: 8395783.
 10. **Vasiliou V**, Reuter SF, Kozak CA, Nebert DW. Mouse Dioxin-inducible cytosolic aldehyde dehydrogenase: Ahd-4 cDNA sequence, genetic mapping, and differences in gene expression. **Pharmacogenetics** 3: 281-290, 1993. PMID: 8148869.
 11. Liu R-M, **Vasiliou V**, Duh L, Puga A, Nebert DW, Sainsbury M, Shertzer HG. Regulation of [Ah] gene battery enzymes and glutathione levels by 5,10-dihydroindeno[1,2b]-indole in mouse hepatoma cell lines. **Carcinogenesis** 15: 2347-2352, 1994. PMID: 7955076.
 12. **Vasiliou V**, Pappas P, Nebert DW, Marselos M. Lack of response of the rat liver class 3 cytosolic aldehyde dehydrogenase to toxic chemicals, glutathione depletion, and other forms of stress. **Biochem Pharmacol** 48: 841-845, 1994. PMID: 8080457.
 13. **Vasiliou V**, Theuer MJ, Puga A, Reuter SF, Nebert DW. Mouse dioxin-inducible NAD(P)H:menadione oxidoreductase: NMO1 cDNA sequence and genetic differences in gene expression. **Pharmacogenetics** 4: 341-348, 1994. PMID: 7704040.
 14. **Vasiliou V**, Reuter SF, Kozak CA, Nebert DW. Mouse Class 3 aldehyde dehydrogenases. **Adv Exp Med Biol** 372: 151-158, 1995. PMID: 7484373.
 15. Pappas P, **Vasiliou V**, Karageorgou M, Stefanou P, Marselos M. Studies on the induction of the rat class 3 aldehyde dehydrogenase. **Adv Exp Med Biol** 372:143-150, 1995. PMID: 7484372.
 16. Shertzer HG, **Vasiliou V**, Liu R-M, Tabor WM, Nebert DW. Enzyme induction by L-buthionine(S,R)-sulfoximine in cultured mouse hepatoma cells. **Chem Res Toxicol** 8: 431-436, 1995. PMID: 7578930.
 17. **Vasiliou V**, Shertzer HG, Liu R-M, SainsburyM, Nebert DW. Response of the [Ah] battery genes to compounds that protect against menadione toxicity. **Biochem Pharmacol** 50: 1885-1891, 1995. PMID: 8615869.
 18. **Vasiliou V**, Karageorgou M, Nebert DW, Marselos M. Ligands of four receptors in the nuclear steroid/thyroid superfamily inhibit induction of rat cytosolic aldehyde dehydrogenase-3 (ALDH3c) by 3-methylcholanthrene. **Biochem Pharmacol** 50: 2113-2217, 1995. PMID: 8849341.

19. **Vasiliou V**, Puga A, Ching-yi Chang, M. Tabor W, Nebert DW. Interaction between the Ah receptor and proteins binding to the AP-1-like electrophile responsive element (EpRE) during the murine phase II [*Ah*] battery gene expression. **Biochem Pharmacol** 50: 2057-2068, 1995. PMID: 8849333.
20. **Vasiliou V**, Weiner H, Marselos M, Nebert DW. Mammalian aldehyde dehydrogenase genes: classification based on evolution, structure and regulation. **Eur J Drug Metab Pharmacokinet** 20: 53-64, 1995.
21. Marselos M, Karageorgou M, Stefanou P, Pappas P, **Vasiliou V**. Hormonal regulation of an inducible aldehyde dehydrogenase. **Eur J Drug Metab Pharmacokinet** 20: 65-68, 1995.
22. **Vasiliou V**, Kozak CA, Lindahl R, Nebert DW. Mouse microsomal Class 3 aldehyde dehydrogenase: Ahd-3 cDNA sequence, chromosomal mapping, and dioxin inducibility. **DNA Cell Biol** 15: 235-245, 1996. PMID: 8634152
23. Marks-Hull H, Shiao, T-Y, Araki-Sasaki K, Traver R, **Vasiliou V**. Expression of ALDH3 and NMO1 in human corneal epithelial and breast adenocarcinoma cells. **Adv Exp Med & Biol** 414: 59-68, 1997. PMID: 9059607.
24. **Vasiliou V**, Reuter S, Shiao T-Y, Puga A, Nebert DW. Mouse-dioxin inducible Ahd4 gene: structure of the 5'flanking region and transcriptional regulation. **Adv Exp Med & Biol** 414: 37-46, 1997. PMID: 9059605.
25. Pappas P, Stephanou P, **Vasiliou V**, Karamanakos P, Marselos M. Ontogenesis and expression of ALDH activity in the skin and the eye of the rat. **Adv Exp Med & Biol** 414: 73-80, 1997. PMID: 9059609.
26. **Vasiliou V**. Aldehyde dehydrogenase genes. **Adv Exp Med & Biol** 414: 595-600, 1997. PMID: 9148643.
27. He X-X, Nebert DW, **Vasiliou V**, Zhu H, Shertzer H. Genetic differences in alcohol preference between inbred strains of mice. **Pharmacogenetics** 7: 223-233, 1997. PMID: 9241662.
28. **Vasiliou V**, Reuter S, Nebert DW. Extrahepatic expression of NAD(P)H:menadione oxidoreductase (NMO1), UDP glucuronosyltransferase -1A6 (UGT1A6), microsomal aldehyde dehydrogenase (AHD3), and hepatic nuclear factor-1a (HNF-1a) mRNAs in *ch/ch* and *14CoS/14CoS* mice. **Biochem Biophys Res Commun** 233: 631-636, 1997. PMID: 9168903.
29. Pappas P, Stefanou P, **Vasiliou V**, Marselos M. Zoxazolamine-paralysis in two rat substrains: Differences in Hepatic drug metabolism. **Eur J Drug Metab Pharmacokinet** 23: 461-467, 1998. PMID: 10323328.
30. Pappas P, Stefanou P, **Vasiliou V**, Marselos M. Anti-inflammatory agents and inducibility of hepatic drug metabolism. **Eur J Drug Metab Pharmacokinet** 23: 457-460, 1998. PMID: 10323327.
31. Ziegler T, **Vasiliou V**. Aldehyde dehydrogenase gene superfamily: The 1998 update. **Adv Exp Med & Biol** 463: 255-263, 1999. PMID: 10352694.
32. **Vasiliou V**, Shiao T. The lack of AHD4 induction by TCDD in corneal cells may involve tissue-specific regulatory proteins. **Adv Exp Med & Biol** 463: 181-188, 1999. PMID: 10352684.
33. Stefanou P, Pappas P, **Vasiliou V**, Marselos M. Prepubertal regulation of the rat dioxin-inducible aldehyde dehydrogenase (ALDH3c). **Adv Exp Med & Biol** 463: 143-150, 1999. PMID: 10352679.
34. Shiao T, Tran P, Siegel D, Lee J, **Vasiliou V**. Four amino acid changes are associated with the *Aldh3a1* locus polymorphism in mice which may be responsible for corneal sensitivity to UV light. **Pharmacogenetics** 9: 145-153, 1999. PMID: 10376761.

35. **Vasiliou V**, Reuter SF, Williams S, Puga A, Nebert DW. Mouse cytosolic class 3 aldehyde dehydrogenase (*Aldh3a1*): Gene structure and regulation of constitutive and dioxin-inducible expression. **Pharmacogenetics** 9: 569-80, 1999. PMID: 10591537.
36. **Vasiliou V**, Bairoch A, Tipton K, Nebert DW. Eukaryotic aldehyde dehydrogenase (*ALDH*) genes: Human polymorphisms, and recommended nomenclature based on divergent evolution and chromosomal mapping. **Pharmacogenetics** 9: 421-434, 1999. PMID: 10780262.
37. **Vasiliou V**, Buetler T, Eaton DL, Nebert DW. Comparison of oxidative stress response parameters in newborn mouse liver versus SV40-transformed hepatocyte cell lines. **Biochem Pharmacol** 59: 703-712, 2000. PMID: 10677587.
38. **Vasiliou V**, Lee J, Pappa A, Petersen DR. Involvement of p65 in the regulation of NF-kappaB in rat hepatic stellate cells during cirrhosis. **Biochem Biophys Res Commun** 273: 546-50, 2000. PMID: 10873642.
39. **Vasiliou V**, Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. **Pharmacology** 61: 192-198, 2000. PMID: 10971205.
40. Reichard JF, **Vasiliou V**, Petersen DR. Characterization of 4-hydroxy-2-nonenal metabolism in stellate cell lines derived from normal and cirrhotic rat liver. **Biochim Biophys Acta** 1487: 222-232, 2000. PMID: 11018474.
41. **Vasiliou V**, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. **Chem Biol Interactions** 129: 1-19, 2000. PMID: 11154732.
42. Pappa A, Sophos NA, **Vasiliou V**. Corneal and stomach aldehyde dehydrogenases: from fish to mammals. **Chem Biol Interactions** 130-132(1-3): 181-191, 2001. PMID: 11306042.
43. Sophos NA, Pappa A, Ziegler T, **Vasiliou V**. Aldehyde dehydrogenase gene superfamily: the 2000 update. **Chem Biol Interactions** 130-132(1-3): 323-37, 2001. PMID: 11306055.
44. Pappas P, Stephanou P, Karamanacos P, **Vasiliou V**, Marselos M. Phenobarbital inducibility and differences in protein expression of an animal model. **Chem Biol Interactions** 130-132(1-3): 275-283, 2001. PMID: 11306051.
45. **Vasiliou V**, Sophos N. ALDH2. **Atlas Genet Cytogenet Oncol Haematol**. September 2001. URL: <http://atlasgeneticsoncology.org/Genes/ALDH2ID250.html>.
50. Manzer A, Pappa A, Estey T, Sladek N, Carpenter JF, **Vasiliou V**. Ultraviolet radiation decreases expression and induces aggregation of corneal ALDH3A1. **Chem Biol Interactions** 143-144: 5-22, 2003. PMID: 12604188.
51. Sophos NA, **Vasiliou V**. Aldehyde dehydrogenase gene superfamily: The 2002 update. **Chem Biol Interactions** 143-144: 45-53, 2003. PMID: 12604184.
52. Pappa A, Chen C, Koutalos Y, Townsend AJ, **Vasiliou V**. ALDH3A1 protects human corneal epithelial cells from ultraviolet- and 4-hydroxy-2-nonenal-induced oxidative damage. **Free Radic Biol & Med** 34: 1178-1189, 2003. PMID: 12706498.
53. Manzer R, Qamar L, Estey T, Pappa A, Petersen DR, **Vasiliou V**. Molecular cloning and expression of the rabbit corneal ALDH1A1. **DNA Cell Biol** 22: 329-338, 2003. PMID: 12941160.
54. **Vasiliou V**, Qamar L, Pappa A, Sophos NA, Petersen DR. Involvement of the electrophile responsive element (EPRE) and p53 in the activation of hepatic stellate cells as a response to electrophile menadione. **Arch Biochem Biophys** 413: 164-171, 2003. PMID: 12729613.
55. Pappa A, Estey T, Manzer R, Brown D, **Vasiliou V**. Human aldehyde dehydrogenase 3A1 (ALDH3A1): Biochemical characterization and immunohistochemical localization in the cornea. **Biochem J** 376: 615-623, 2003. PMCID: PMC1223798.

56. DiFabio J, Ji Y, **Vasiliou V**, Thatcher GR, Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. **Mol Pharmacol** 64: 1109-1116, 2003. PMID: 14573760.
57. **Vasiliou V**, Pappa Agi, Estey T: Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. **Drug Metab Rev** 36: 279-299, 2004. PMID: 15237855.
58. Mashek DG, Bornfeldt KE, Coleman RA, Berger J, Bernlohr DA, Black P, DiRusso CC, Farber SA, Guo W, Hashimoto N, Khodiyar V, Kuypers FA, Maltais LJ, Nebert DW, Renieri A, Schaffer JE, Stahl A, Watkins PA, **Vasiliou V**, Yamamoto TT. Revised nomenclature for the mammalian long chain Acyl-CoA synthetase (ACS) gene family. **J Lipid Res** 45: 1958-61, 2004. PMID: 15292367.
59. Nebert DW, Sophos NA, **Vasiliou V**, Nelson DR. Cyclophilin nomenclature problems, or, "a visit from the sequence police". **Hum Genomics** 1: 381-388, 2004. PMCID: PMC3525097.
60. Nebert DW, **Vasiliou V**: Analysis of the glutathione S-transferase (GST) gene family. **Hum Genomics** 1: 460-464, 2004. PMCID: PMC3500200.
61. Kenney M. C, Chwa M, Atilano S, Tran A, Carballo M, Saghizadeh M, **Vasiliou V**, Adachi W, Brown DJ. Increased catalase and cathepsin V/L2 but decreased TIMP-1 in keratoconus corneas: Evidence that oxidative stress plays a role in this disorder. **Invest. Ophthalmol Vis Sci** 46: 823-832, 2005. PMID: 15728537.
62. Gurwitz D, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Kirchheiner J, Licinio J, Llerena A, Manolopoulos VG, Sheffield LJ, Siest G, Torricelli F, **Vasiliou V**, Wong S. Pharmacogenomics education: ISP recommendations for medical, pharmaceutical, and health schools Deans of Education. **Pharmacogenomics J** 5: 221-225, 2005. PMID: 15852053.
63. Lassen N, Estey T, Tanguay R, Pappa A, Reimer MJ, **Vasiliou V**. Molecular cloning, baculovirus expression and tissue distribution of the zebrafish ALDH2. **Drug Metab Dispos** 33: 649-56, 2005. PMID: 15703303.
64. **Vasiliou V**, Nebert DW. Analysis and update of the human aldehyde dehydrogenase family. **Hum Genomics** 2: 138-143, 2005. PMCID: PMC3255259.
65. Pappa A, Brown D, Koutalos Y, Degregori J, White C, **Vasiliou V**. Human aldehyde dehydrogenase 3A1 (ALDH3A1) inhibits proliferation and promotes survival of human corneal epithelial cells. **J Biol Chem** 280: 27998-28006, 2005. PMID: 15905174.
66. Black W, **Vasiliou V**. Ocular metabolism and disposition of 4-hydroxyl-2-nonenal. **Cutaneous and Ocular Toxicology** 24: 155-176, 2005.
67. **Vasiliou V**, Ziegler TL, Bludeau P, Petersen DR, Gonzalez FJ, Deitrich RA. CYP2E1 and catalase influence ethanol sensitivity in the central nervous system. **Pharmacogenet Genomics** 16:51-8, 2006. PMID: 16344722.
68. Panayiotidis MI, Stabler SP, Ahmad A, Pappa A, Legros LH, Hernandez D, Schneider K, Allen RH, **Vasiliou V**, McCord JM, Kotb M, White CW. Activation of a novel isoform of methionine adenosyltransferase 2A and increased S-adenosylmethionine turnover in lung epithelial cells exposed to hyperoxia. **Free Radic Biol & Med** 40: 348-58, 2006. PMID: 16413417.
69. **Vasiliou V**, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. **Hum Genomics** 2: 329-335, 2006. PMCID: PMC3500182.
70. Muzio G, Trombetta A, Maggiora M, Martinasso G, **Vasiliou V**, Lassen N, Canuto RA. Arachidonic acid suppresses growth of human lung tumor A549 cells through down regulation of ALDH3A1 expression. **Free Radic Biol & Med** 40: 1929-38, 2006. PMID: 16716894.
71. Zimatkin SM, Pronko PS, **Vasiliou V**, Gonzalez FJ, Deitrich RA. Enzymatic mechanisms of

- ethanol oxidation in the brain of rats and mice. **Alc Clin Exp Res** 30: 1500-1505, 2006. PMID: 16930212.
72. Horwitz J, Ding L, **Vasiliou V**, Cantore M, Piatigorsky J. Scallop lens Ω -crystallin (ALDH1A9): A novel tetrameric aldehyde dehydrogenase. **Biochem Biophys Res Commun** 348: 1302-1309, 2006. PMID: 16919242.
 73. Bhave SV, Hoffman PL, Lassen N, **Vasiliou V**, Deitrich RA, Tabakoff B. Gene array profiles of alcohol and aldehyde metabolizing enzymes in brain of mice which differ in their response to ethanol. **Alc Clin Exp Res** 10: 1-11, 2006. PMID: 17010133.
 74. Lassen N, Pappa A, Black WJ, Jester JV, Day B, Min E, **Vasiliou V**. Antioxidant function of corneal ALDH3A1 in cultured stromal fibroblasts. **Free Radic Biol & Med** 41:1459-69, 2006. PMID: 17023273.
 75. Estey T, Piatigorsky J, Lassen N, **Vasiliou V**. ALDH3A1: a corneal crystallin with diverse functions. **Exp Eye Res** 84: 3-12, 2007. PMID: 16797007.
 76. Estey T, Weston PA, Cantore M, Carpenter J, Petrash JM, **Vasiliou V**. Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. **J Biol Chem** 282: 4382-92, 2007. PMID: 17158879.
 77. Marchitti SA, Deitrich RA, **Vasiliou V**. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde (DOPAL) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL): The role of aldehyde dehydrogenase. **Pharmacol Reviews** 59: 125-50, 2007. PMID 17379813.
 78. Marchitti SA, Orlicky DJ, **Vasiliou V**. Expression and initial characterization of human ALDH3B1. **Biochem Biophys Res Commun** 356: 792-798, 2007. PMCID: PMC1899873.
 79. Jia S, Omelchenko S, Garland D, **Vasiliou V**, Kanungo J, Spencer M, Koonin E, Piatigorsky, J. Duplicated gelsolin-family genes in zebrafish: a novel scinderin-like gene (*scinla*) encodes the major corneal crystallin. **FASEB J** 21: 3318-28, 2007. PMID: 17548429.
 80. Lassen N, Bateman BJ, Estey T, Kuszak JR, Nees D, Piatigorsky J, Duester G, Day B, Huang J, Hines L, **Vasiliou V**. Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in *Aldh1a1^{-/-}/Aldh3a1^{-/-}* knockout mice. **J Biol Chem** 282: 25668-76, 2007. PMCID: PMC2253645.
 81. **Vasiliou V**, Gonzalez FJ. The role of CYP1B1 in glaucoma. **Ann Rev Pharmacol Toxicol** 48:333-358, 2008. PMID: 17914928.
 82. Lassen N, Black WJ, Estey T, **Vasiliou V**: The role of corneal crystallins in the cellular defense mechanisms against oxidative stress. **Semin Cell Dev Biol** 19: 100-12, 2008. PMID: 18077195.
 83. Marchitti SA, Brocker C, Stagkos D, **Vasiliou V**. Non-P450 alcohol and aldehyde metabolizing enzymes. **Expert Opinion Drug Metab & Toxicol** 4: 697-720, 2008. PMCID: PMC2658643.
 84. D'Amelio S, Lassen N, **Vasiliou V**, Bateman BJ. Duane Retraction Syndrome, Nystagmus, Retinal Pigment Epitheliopathy and Epiretinal Membrane with Micro- and Pachygyria, Developmental Delay, Hearing Loss and Craniopharyngioma. **Ophthalmic Genetics** 30: 7-12, 2009. PMID: 19172504.
 85. Stagkos D, Zhou H, Ross D, Piatigorsky J, **Vasiliou V**. 4-Hydroxynonenal inhibits angiogenesis *in vitro* and up-regulates Chondromodulin-I. **Biochem Biophys Res Commun** 379: 654-58, 2009. PMCID: PMC2757412.
 86. Xiao T, Shoeb M, Zhang M, Ramana KV, Srivastava SK, **Vasiliou V**, Ansari NA. Molecular cloning and oxidative modification of human lens ALDH1A1: Implication in impaired detoxification of lipid aldehydes. **J Toxicol Environ Health A** 72: 577-84, 2009. PMID: 19296407.

87. **Vasiliou V**, Vasiliou K, Nebert DW, Human ATP-binding cassette (ABC) transporter family. **Hum Genomics** 3: 281-90, 2009. PMID: PMC2752038.
88. Chen Y, Johansson E, Fan Y, Shertzer HG, **Vasiliou V**, Nebert DW, Dalton TP. Early onset senescence occurs when fibroblasts lack glutamate cysteine ligase modifier subunit. **Free Radic Biol Med** 47: 410-8, 2009. PMID: PMC2773044.
89. Chen Y, Mehta G, **Vasiliou V**. Antioxidant defenses in ocular surface. **Ocul Surf** 7: 176-185, 2009. PMID: PMC4104792.
90. Black W, Stagos D, Marchitti SA, Nebert DW, Tipton K, Bairoch A, **Vasiliou V**. Human aldehyde dehydrogenase genes: alternatively spliced transcriptional variants and their suggested nomenclature. **Pharmacogenet Genomics** 19: 893-902, 2009. PMID: PMC3356695.
91. Brocker CN, **Vasiliou V**, Nebert DW, Evolutionary divergence and functions of the *ADAM* and *ADAMTS* gene families. **Hum Genomics** 4: 43-55, 2009. PMID: PMC3500187.
92. Endo J, Sano M, Katayama T, Hishiki T, Shinmura K, Morizane S, Matsuhashi T, Katsumata Y, Zhang Y, Ito H, Nagahata Y, Marchitti S, Nishimaki K, Wolf AM, Nakanishi H, Hattori F, **Vasiliou V**, Adachi T, Ohsawa I, Taguchi R, Hirabayashi Y, Ohta S, Suematsu M, Ogawa S, Fukuda K. Metabolic remodeling induced by mitochondrial aldehyde stress stimulates tolerance to oxidative stress in the heart. **Circ Res** 105: 1118-27, 2009. PMID: 19815821.
93. Black W, **Vasiliou V**. The aldehyde dehydrogenase gene superfamily resource center. **Hum Genomics** 4: 136-142, 2009. PMID: PMC3525204.
94. Stagos D, Chen Y, Cantore M, Jester JV, **Vasiliou V**, Corneal aldehyde dehydrogenases: Multiple functions and novel nuclear localization. **Brain Res Bull** 81: 211-218, 2010. PMID: PMC3025408.
95. Jackson BC, Nebert DW, **Vasiliou V**. Update of human and mouse matrix metalloproteinase families. **Hum Genomics** 4: 194-201, 2010. PMID: PMC3525976.
96. Brocker C, Lassen N, Estey T, Pappa A, Cantore M, Orlova VV, Chavakis T, Kavanagh KL, Oppermann U, **Vasiliou V**. Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. **J. Biol Chem** 285: 18452-63, 2010. PMID: PMC2881771.
97. Marchitti SA, Orlicky DJ, **Vasiliou V**, Aldehyde dehydrogenase 3B1 (ALDH3B1): Immunohistochemical tissue distribution and cellular-specific localization in normal and cancerous human tissues. **J Histochem Cytochem** 58: 765-83, 2010. PMID: PMC2924794.
98. Jackson BC, Carpenter C, Nebert DW, **Vasiliou V**. Update of human and mouse forkhead box (FOX) gene families. **Hum Genomics** 4: 345-52, 2010. PMID: PMC3500164.
99. Stagos D, Chen Y, Brocker, C, Donald E, Jackson BC, Orlicky D, Thompson D, **Vasiliou V**, Aldehyde dehydrogenase 1B1 (ALDH1B1): Molecular cloning and characterization of a novel mitochondrial acetaldehyde metabolizing enzyme. **Drug Metab Dispos** 38: 1679-87, 2010. PMID: PMC2957164.
100. Brocker C, Carpenter C, Nebert DW, **Vasiliou V**. Evolutionary divergence and functions of the human acyl-CoA thioesterase gene (*ACOT*) family. **Hum Genomics** 4: 411-20, 2010. PMID: PMC3525216.
101. Marchitti SA, Brocker C, Orlicky D, **Vasiliou V**. Molecular characterization, expression analysis and the role of ALDH3B1 in cellular defense against oxidative stress, **Free Radic Biol Med** 49: 1432-43, 2010. PMID: PMC3457645.
102. Scharer G, Brocker C, **Vasiliou V**, Creadon-Swindell G, Gallagher RC, Spector E, Van Hove JLK.

- The genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy due to mutations in ALDH7A1. **J Inherit Metab Dis** 33: 571-8, 2010. PMID: PMC3112356.
103. Chen Y, Johansson E, Yang Y, Miller ML, Shen D, Stringer KF, Shertzer HG, Nebert DW, **Vasiliou V**, and Dalton TP. Oral *N*-acetylcysteine rescues lethality of hepatocyte-specific *Gclc* knockout mice providing a model for hepatic cirrhosis. **J Hepatol** 53: 1085-94, 2010. PMID: PMC2970663.
 104. Estey T, Chen Y, Carpenter J, **Vasiliou V**. Structural and functional modifications of corneal crystallin ALDH3A1 by UVB light. **PLoS ONE** 5: e15218, 2010. PMID: PMC3006428.
 105. Brocker C, Thompson D, Matsumoto A, Nebert DW, **Vasiliou V**. Evolutionary divergence and functions of the human interleukin (IL) gene family. **Hum Genomics** 5:30-55, 2010, PMID: PMC3390169.
 106. Chen Y, Orlicky DJ, Matsumoto A, Singh S, Thompson DC, **Vasiliou V**. Aldehyde dehydrogenase 1B1 (ALDH1B1) is a potential biomarker for human colon cancer. **Biochem Biophys Res Commun**, 405(2): 173-9, 2011. PMID: PMC3112362.
 107. Oraldi M, Saracino S, Maggiora M, Chiaravalloti A, Buemi C, Martinasso G, Paiuzzi E, Thompson DC, **Vasiliou V**, Canuto RA. Importance of inverse correlation between ALDH3A1 and PPAR γ in tumour cells and tissue regeneration. **Chemico-Biol Interact** 191: 171-176, 2011. PMID: 21251908.
 108. Brocker C, Cantore M, Failli P, **Vasiliou V**. Aldehyde dehydrogenase 7A1 (ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity. **Chemico-Biol Interact** 191: 269-277, 2011. PMID: PMC3387551.
 109. Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, **Vasiliou V**. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. **Hum Genomics** 5: 283-303, 2011. PMID: PMC3392178.
 110. Marchitti S, Chen Y, Thompson DC, **Vasiliou V**. Ultraviolet radiation: cellular antioxidant response and the role of ocular aldehyde dehydrogenase enzymes. **Contact Eye Lens** 37: 206-213, 2011. PMID: PMC3356694.
 111. Khanna M, Chen CH, Kimble-Hill A, Parajuli B, Perez-Miller S, Baskaran S, Kim J, Dria K, **Vasiliou V**, Rosen DM, and Hurley TD. Discovery of a novel class of suicide inhibitor for aldehyde dehydrogenases. **J. Biol Chem** 286: 43486–4349, 2011. PMID: PMC3234859.
 112. Jackson BJ, David C, Thompson DC, Wright MW, McAndrews M, Bernard A, Nebert DW, **Vasiliou V**. Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom of androgen-binding protein genes within the mouse Scgb gene superfamily. **Hum Genomics** 5: 691-702, 2011. PMID: PMC3251818.
 113. Chen Y, Thompson DC, **Vasiliou V**. Focus on molecules: ALDH1A1 from lens and corneal crystallin to stem cell marker. **Exp. Eye Res** 102: 105-6, 2011. PMID: PMC3423494.
 114. Monte AA, Heard KJ, **Vasiliou, V**. Prediction of drug response and toxicity in clinical practice. **J Med Toxicol** 8: 43-51, 2012. PMID: PMC3550218.
 115. Gasparetto M, Sekulovic S, Brocker C, Tang P, Zakaryan A, Xiang P, Kuchenbauer F, Wenn M, Katayoon K, Witty MF, Rosten P, Chen Y, Imren S, Duyster G, Thompson DC, Humphries RK, **Vasiliou V**, Smith C. Aldehyde dehydrogenases are regulators of hematopoietic stem cell numbers and B-cell development. **Exp. Hematol** 40:3 18-329, 2012. PMID: 22198153.
 116. Zhang J-X, Li D-Q, He AR, Motwani M, **Vasiliou V**, Eswaran J, Mishra L, Kumar R. Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and

- poly (ADP-ribose) polymerases. **Hepatology** 55: 1840-51, 2012. PMID: PMC3470855.
117. Jester JV, Nien C, Flynn K, Wahlerl A, Brown D, Pappa A, **Vasiliou V**. Myofibroblast differentiation modulates keratocyte crystallin protein expression, concentration and cellular light scattering. **Invest Ophthalmol Vis Sci** 53 :770-8, 2011. PMID: PMC3317419.
 118. Black WJ, Chen Y, Matsamoto A, Lassen N, Pappa A, Thompson DC, Vasiliou, V. Molecular mechanisms of ALDH3A1-mediated cellular protection against 4-hydroxy-2-nonenal. **Free Radic Biol Med** 52: 1937-44, 2012. PMID: PMC3457646.
 119. Zhang Y, Mao L, Wang H, Brocker C, Xiangjing Yin Xn, **Vasiliou V**, Fei Z, Xiping Wan X. Genome-wide identification and analysis of grape aldehyde dehydrogenase (ALDH) gene superfamily. **Plos One** 7: e32153, 2012. PMID: PMC3280228.
 120. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, Petersen DR, Dietrich RA, Hurley TD, **Vasiliou V**. Aldehyde Dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity and clinical application. **Pharmacol Rev** 64: 520-39, 2012. PMID: PMC3400832.
 121. Jester JV, Nien C-J, **Vasiliou V**, Brown DJ. Quiescent keratocytes fail to repair MMC induced DNA damage leading to the long-term inhibition of myofibroblast differentiation and wound healing. **Mol Vis** 18:1828-39, 2012, PMID: PMC3398499.
 122. Gasparetto M, Sekulovic S, Zakaryan A, Imren S, Humphries SK, **Vasiliou V**, Smith C. Varying levels of aldehyde dehydrogenase activity in murine marrow hematopoietic stem cells is associated with engraftment and cell cycle status. **Exp Hematol** 40: 857-66, 2012. PMID: 22683567.
 123. Brocker C, Thompson DC, **Vasiliou V**. The role of hyperosmotic stress in inflammation and disease. **Biomol Concepts** 3: 345–364, 2012. PMID: PMC3438915.
 124. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Gonzalez R, Norris DA, Roop DR, **Vasiliou V**, Fujita M. ALDH is a marker of human melanoma stem cells and a potential therapeutic target. **Stem Cells** 30: 2100-13, 2012. PMID: PMC3448863.
 125. Saw Y-T, Yang J, Ng S-K, Liu S, Singh S, Singh M, Welch WR, Tsuda H, Fong W-P, Thompson DC, **Vasiliou V**, Berkowitz RS, Ng S-W. Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. **BMC Cancer** 12: 329, 2012. PMID: PMC3458927.
 126. Ku CS, **Vasiliou V**, Cooper DN. A new era in the discovery of de novo mutations underlying human genetic disease. **Hum Genomics** 6: 27, 2012. PMID: PMC3538533
 127. Monte AA, **Vasiliou V**, Heard KJ. Omics screening for pharmaceutical efficacy and safety in clinical practice. **J Pharmacogenomics Pharmacoproteomics** 2012, S5, PMID: 23264882. PMID: PMC3526192.
 128. Brocker C, Vasiliou M, Carpenter S, Carpenter C, Zhang Y, Wang X, Kotchoni SO, Wood AJ, Kirch HH, Kopeny D, Nebert DW, **Vasiliou V**. Aldehyde dehydrogenase (ALDH) superfamily in plants: Gene nomenclature and comparative genomics. **Planta** 237: 189-210, 2013. PMID: PMC3536936.
 129. Chen Y, Thompson DC, Koppaka V, Jester JV, **Vasiliou V**. Ocular aldehyde dehydrogenases: protection against ultraviolet damage and maintenance of transparency for vision. **Prog Retin Eye Res** 33: 28-39, 2013. PMID: PMC3570594.
 130. Ioannou M, Serafimidis I, Sussel L, Arnes L, Singh S, **Vasiliou V**, Gavalas A. ALDH1B1 is a potential stem/progenitor marker for multiple pancreas progenitor pools. **Developmental Biol** 374: 153-63, 2013. PMID: PMC3580293.

131. **Vasiliou V**, Thompson DC, Smith C, Fujita M, Chen Y. Aldehyde dehydrogenases: From eye crystallins to metabolic disease and stem cells. *Chem Biol Interact* 202: 2-10, 2013. PMID: PMC4128326.
132. Singh S, Brocker C, Koppaka V, Chen Y, Jackson B, Matsumoto A, Thompson DC, **Vasiliou V**. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. *Free Radic Biol Med* 56: 89-101, 2013. PMID: PMC3631350.
133. Bchini R, **Vasiliou V**, Guy Branlant G, Talfournier F, Rahuel-Clermont S. Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition. *Chem Biol Interact* 202: 78-84, 2013. PMID: PMC3602353.
134. Heit C, Dong H, Chen Y, Thompson DC, Deitrich RA, **Vasiliou V**. The role of CYP2E1 in alcohol metabolism and sensitivity in the central nervous system. *Subcell Biochem* 67: 235-47, 2013. PMID: PMC4314297.
135. Jackson BC, Holmes RS, Backos DS, Reigan P, **Vasiliou V**. Comparative genomics and molecular modeling of ALDH2 and ALDH1B1: Evidence for early vertebrate origin of ALDH1B1 from the ALDH2 gene and protein heterodimerization. *Chem Biol Interact* 202: 11-21, 2013. PMID: PMC3687035.
136. **Vasiliou V**, Sandoval M, Backos DS, Jackson BC, Chen Y, Reigan P, Lanaspas MA, Johnson RJ, Koppaka V, Thompson DC. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1. *Chem Biol Interact* 202: 22-31, 2013. PMID: PMC3746320.
137. Dong, H; Shertzer HG, Genter MB, PhD; Gonzalez FJ, **Vasiliou V**, Jefcoate C, Nebert DW, Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins. *Biochem Biophys Res Commun* 435(4):727-32, 2013, PMID: PMC3735136.
138. LaGier AL, Gordon GM, Katzman LR, **Vasiliou V**, Fini ME, Mechanisms for PDGF, a serum cytokine, stimulating loss of corneal keratocyte crystallins. *Cornea* 32: 1269-1275, 2013. PMID: PMC3874843.
139. Patrinos GP, Baker DJ, Al-Mulla F, **Vasiliou V**, Cooper DN. Genetic tests obtainable through pharmacies: the good, the bad and the ugly. *Hum Genomics* 7: 17, 2013. PMID: PMC3711749.
140. Chen Y, Dong H, Thompson DC, Shertzer HG, Nebert DW, **Vasiliou V**. Glutathione defense mechanism in liver injury: insights from animal models. *Food Chem Toxicol* 60: 38-44, 2013. PMID: PMC3801188.
141. Heit C, Jackson BC, McAndrews M, Wright MW, Thompson DC, Silverman GA, Nebert DW, **Vasiliou V**. Update of the human and mouse SERPIN gene superfamily. *Hum Genomics* 7: 22, 2013. PMID: PMC388077.
142. Jang JH, Bruse S, Liu Y, Duffy V, Zhang C, Lin Y, Randell SH, Thompson DC, **Vasiliou V**, Tesfaigzi Y, Nyunoya T. Aldehyde dehydrogenase 3A1 protects airway epithelial cells from cigarette smoke-induced DNA damage and cytotoxicity. *Free Radic Biol Med* 68: 80-86, 2014. PMID: PMC3941192.
143. Kwon H-J, Won Y-S, Park O, Duryee MJ, Thielle GE, Matsumoto A, Sigh S, Kawamoto T, Abdelmegeed MA, Song BJ, **Vasiliou V**, Thiele GM, Gao B. Aldehyde dehydrogenase 2 deficiency ameliorates fatty liver but exacerbates liver inflammation and fibrosis in mice. *Hepatology* 60(1): 146-57, 2014. PMID: PMC4077916.
144. Smith C, Gasparetto M, Humphries K, Pollyea DA, **Vasiliou V**, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. *Ann N Y Acad Sci* 1310: 58-68, 2014. PMID:

- 24641679.
145. Matsumoto A, **Vasiliou V**, Kawamoto T; Tanaka K; Ichiba M. Ethanol reduces lifespan, body weight, and serum alanine aminotransferase level of aldehyde dehydrogenase 2 knockout mouse. **Alcohol Clin Exp Res** 38: 1883-93, 2014. PMID: 24930774.
 146. Babcock HE, Dutta S, Alur RP, Brocker C, **Vasiliou V**, Vitale S, Brooks BP. Aldh7a1 regulates eye and limb development in zebrafish. **PLoS One** 9(7): e101782, 2014. PMCID: PMC4086958.
 147. Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, **Vasiliou V**. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. **Acad Emerg Med** 8:879-885, 2014. PMCID: PMC4150819.
 148. Monte AA, Heard KJ, Hoppe JA, **Vasiliou V**, Gonzalez FJ. The accuracy of self-reported drug ingestion histories in emergency department patients. **J Clin Pharmacol** 55: 33-8, 2014. PMCID: PMC4276443.
 149. Monte AA, Brocker C, Nebert DW, Gonzalez FJ, Thompson DC, **Vasiliou V**, Improved drug therapy: triangulating phenomics with genomics and metabolomics. **Hum Genomics** 8: 16, 2014. PMCID: PMC4445687.
 150. Smith CC, Gasparetto M, Craig Jordan C, Pollyea DA, **Vasiliou V**. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. **Adv Exp Med Biol** 815: 349-59, 2015. PMID: 25427917.
 151. Singh S, Arcaroli J, Thompson DC, Messersmith W, **Vasiliou V**. Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers. **Adv Exp Med Biol** 815: 281-94, 2015. PMCID: PMC4347404.
 152. Heit C, Dong H, Chen Y, Shah Y, Thompson DC, **Vasiliou V**, Transgenic mouse models for alcohol metabolism, toxicity and cancer. **Adv Exp Med Biol** 815: 375-87, 2015. PMCID: PMC4323349.
 153. Jackson BC, Reigan P, Thompson DC, **Vasiliou V**. Human ALDH1B1 polymorphisms may affect the metabolism of nitroglycerin and all-trans retinaldehyde - in vitro studies and computational modeling. **Pharm Res** 32: 1648-62, 2015. PMID: 25413692, PMC4382438.
 154. Singh S, Arcaroli J, Chen Y, David C. Thompson DC, Messersmith W, Antonio Jimeno A and **Vasiliou V**. ALDH1B1 is crucial for colon tumorigenesis by modulating Wnt/ β -catenin, notch and PI3K/Akt signaling pathways. **PLoS One** 10(5): e0121648, 2015. PMID: 25950950. PMCID: PMC4423958.
 155. Singh S, Chen Y, Matsumoto A, Orlicky DJ, Dong H, Thompson DC, **Vasiliou V**. ALDH1B1 links alcohol consumption and diabetes. **Biochem Biophys Res Commun** 463: 768-73, 2015. PMID: 26086111; PMCID4517591.
 156. Yang S-M, Yasgar A, Miller B, Lal M, Brimacombe K, Hu X, Sun H, Wang A, Xu X, Nguyen K, Oppermann U, Ferrer M, **Vasiliou V**, Simeonov A, Jadhav A, David J. Maloney DJ. Discovery of NCT-501. A potent and selective theophylline-based inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1). **J Med Chem** 58: 5967-78, 2015. PMID: 26207746, PMC5185321.
 157. Jackson BC, Thompson DC, Charkoftaki G, **Vasiliou V**. Dead enzymes in the aldehyde dehydrogenase gene family: Role in drug metabolism and toxicology. **Expert Opin Drug Metab Toxicol** 11: 1839-47, 2015. PMID: 26558415, PMC4937717
 158. Dong H, Nebert DW, Bruford EB, Thompson DC, Joenje H, **Vasiliou V**. Update of the human and mouse Fanconi anemia genes. **Hum Genomics** 9: 32, 2015. PMCID: PMC4657327.
 158. Singh S, Arcaroli JJ, Orlicky DJ, Chen Y, Messersmith WA, Bagby S, Purkey A, Quackenbush KS,

- Thompson DC, Vasilis **Vasiliou V**. ALDH1B1 as a modulator of pancreas adenocarcinoma. **Pancreas** 45: 117-22, 2016. PMID: 26566217; PMC5175203.
159. Koppaka V, Ying Chen, Mehta G, Lassen N, Orlicky DJ, Thompson DC, **Vasiliou V**. ALDH3A1 plays a functional role in maintenance of corneal epithelial homeostasis. **PLoS One** 11(1): e0146433, 2016. PMID: 26751691, PMCID: PMC4708999.
 160. Matsumoto A, Thompson D, Chen Y, **Vasiliou V**, Kawamoto T, Ichiba M. Heme oxygenase 1 protects ethanol-administered liver tissue in *Aldh2* knockout mice. **Alcohol** 52: 49-54, 2016. PMID: 27139237.
 161. Heit C, Eriksson P, Thompson DC, Charkoftaki G, Fritz K, **Vasiliou V**. Quantification of neural ethanol and acetaldehyde using headspace GCMS. **Alcohol Clin Exp Res** 40: 1825-31, 2016. PMID: 27501276, PMCID: PMC5008984.
 162. Chen Y, Singh S, Matsumoto A, Manna SK, Abdelmegeed MA, Golla S, Murphy RC, Dong H, Song BJ, Gonzalez FJ, Thompson DC, **Vasiliou V**. Redox activation of LKB1-AMPK pathway protects against alcohol-induced steatosis. **Sci Rep** 6: 29743, 2016. PMCID: PMC4940737.
 163. Dong H, Nebert DW, Bruford EB, Thompson DC, Joenje H, **Vasiliou V**. Letter to the editor for "Update of the human and mouse Fanconi anemia genes". **Hum Genomics** 10: 25, 2016. PMCID: PMC4932714.
 164. Keysar SB, Le NP, Miller B, Kim J, Eagles JR, Cera Nieto C, Tang B, Glogowska MJ JJ, Jackson BC, Anderson RT, Padilla-Just N, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Tan A-C, Serracino H, **Vasiliou V**, Roop DR, Wang X-J, and Jimeno A. Regulation of head and neck squamous cancer stem cells by PI3K and SOX2. **J Natl Cancer Inst** 109, pii: djw189, 2017. PMID: 27634934; PMC5025278.
 165. Matsumoto A, Thompson DC, Chen Y, Kitagawa K, Vasiliou, V. Roles of defective ALDH2 polymorphism on liver protection and cancer development. **Environ Health Prev Med** 21: 395-402, 2016. PMID: 27714678, PMCID: PMC5112207.
 166. Heit C, Marshall S, Singh S, Yu X, Charkoftaki G, Zhao H, Orlicky D, Fritz KS, **Vasiliou V**. Catalase deletion promotes pre-diabetic phenotype in mice. **Free Radic Biol Med** 103: 48-56, 2017. PMID: 27939935.
 167. Berríos-Cárcamo P, Quintanilla M, Herrera-Marschitz M, **Vasiliou V**, Zapata-Torres G, Rivera-Meza M. Racemic salsolinol and its enantiomers act as agonists of the μ -opioid receptor by activating the Gi protein-adenylate cyclase pathway. **Front Behav Neurosci** 10: 253, 2017. PMCID: PMC5253357, PMID: 28167903.
 168. Mak TW, Grusdat M, Duncan GS, Dostert C, Nonnenmacher Y, Cox M, Binsfeld C, Hao Z, Brüstle A, Itsumi M, Jager C, Chen Y, Pinkenburg O, Camara B, Ollert M, Bindslev-Jensen C, **Vasiliou V**, Gorrini C, Lang PA, Lohoff M, Harris IS, Hiller K, Brenner D. Glutathione primes T cell metabolism for inflammation. **Immunity** 46: 675-689, 2017. PMID: 28423341.
 169. Yasgar A, Titus SA, Wang Y, Danchik C, Yang SM, **Vasiliou V**, Jadhav A, Malone DJ, Simeonov A, Martinez NJ. A high-content assay enables the automated screening and identification of small molecules with specific ALDH1A1-inhibitory activity. **PLoS One** 12: e0170937, 2017. PMID: 28129349, PMCID: PMC5271370.
 170. Chen Y, Jester J, Anderson D, Marcitti S, Schey KL, Thompson DC, **Vasiliou V**. Corneal haze phenotype in *Aldh3a1*-null mice: In vivo confocal microscopy and tissue imaging mass spectrometry. **Chem Biol Interact** 276: 9-14, 2017. PMID: 28038895.
 171. Charkoftaki G, Chen Y, Han M, Sandoval M, Yu X, Zhao H, Orlicky DJ, Thompson DC, **Vasiliou V**. Transcriptomic analysis and plasma metabolomics in *Aldh16a1*-null mice reveals a potential

- role of ALDH16A1 in renal function. **Chem Biol Interact** 276: 15-22, 2017. PMID: 28254523.
172. Rattray, J.W.R., Charkoftaki, G, Rattray, Z., Hanes, J.E., Vasiliou, V., Johnson, C.H. Environmental influences in the etiology of colorectal cancer: the premise of metabolomics, **Curr Pharmacol Rep** 3: 114-125, 2017. PMID: 28642837.
 173. Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea D, Myers JR, Ashton JM, Becker MS, **Vasiliou V**, Humphries KR, Jordan CT and Smith CA. Targeted therapy for a subset of acute myeloid leukemia's that lack expression of aldehyde dehydrogenase 1A1. **Haematologica** 102: 1054-1065, 2017. PMID: 28280079.
 174. Matsumoto A, Arcaroli J, Chen Y, Gasparetto M, Neumeister V, Thompson DC, Singh S, Smith C, Messersmith W, **Vasiliou V**. Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer. **Br J of Cancer** 17: 1537-1543, 2017. PMID: 28881356.
 175. Charkoftaki G, Jester J, Thompson D, **Vasiliou V**. Nitrogen mustard-induced corneal injury involves the sphingomyelin-ceramide pathway. **Ocul Surf** 16: 154-162, 2018. PMID: 29129753.
 176. Johnson CH, Athersuch TJ, Collman GW, Dhungana S, Grant DF, Jones DP, Patel CJ, **Vasiliou V**. Yale School of Public Health Symposium on Lifetime Exposures and Human Health: The exposome; summary and future reflections. **Hum Genomics** 11: 32, 2017. PMCID: PMC5723043.
 177. Rattray NJW, Deziel NC, Wallach JD, Khan SA, **Vasiliou V**, Ioannidis JPA, Johnson CH. Beyond genomics: Understanding exposotypes through metabolomics. **Hum Genomics** 12: 4, 2018. PMID: 29373992.
 178. Yang S-M, Martinez NJ, Yasgar A, Danchik C, Wang Y, Baljinnyam B, Wang A, Xu X, Hughes E, Shah P, Cheff D, Wang X, Roth J, Lal-Nag M, **Vasiliou V**, Simeonov A, Jadhav A, Maloney DJ. Discovery of orally bioavailable, quinoline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with potent cellular activity. **Med Chem** 61: 4883-4903, 2018. PMID: 29767973.
 179. Inayat-Hussain SH, Fukumura M, Aziz MA, Jin CM, Jin LW, Rolando Garcia-Milian R, **Vasiliou V**, Deziel NC. Prioritization of reproductive toxicants in unconventional oil and gas operations using a multi-country regulatory data-driven hazard assessment. **Environment International** 117: 348-358, 2018. PMID: 29793188.
 180. Chen Y, Han M, Matsumoto A, Wang Y, Thompson DC, **Vasiliou V**, Glutathione and transsulfuration in alcohol-associated tissue injury and carcinogenesis. **Adv Exp Med Biol** 1032: 37-53, 2018. PMID: 30362089, PMCID: PMC6743726.
 181. Marshall S, Chen Y, Singh S, Berrios-Carcamo P, Heit C, Apostolopoulos N, Golla JP, Thompson DC, **Vasiliou V**. Engineered animal models designed for investigating ethanol metabolism, glutathione homeostasis toxicity and cancer. **Adv Exp Med Biol** 1032: 203-22, 2018. PMID: 30362100.
 182. Lian G, Gnanaprakasam JNR, Wang T, Wu R, Chen X, Liu L, Shen Y, Yang M, Yang J, Chen Y, **Vasiliou V**, Douglas R. Green DR, Liu Y, Wang R. Glutathione de novo synthesis but not recycling process coordinates with glutaminolysis to control redox homeostasis and directs T cell differentiation. **eLife** 7: e36158, 2018. PMCID: PMC6152796.
 183. Perkins AN, Deziel NC, Inayat-Hussain SH, Johnson CH, Stephen S. Ferguson SS, Boyles AL, Thompson DC, **Vasiliou V**. Evaluation of potential carcinogenicity of chemicals in synthetic turf crumb rubber. **Environmental Res** 169: 163-172, 2019. PMID: 30458352.
 184. Matsumoto A, Ito S, Wakamatsu K, Ichiba M, **Vasiliou V**, Akao C, Song BJ, Fujita M. Ethanol induces skin hyperpigmentation in mice with aldehyde dehydrogenase 2 deficiency. **Chemico-Biol Interact** 302: 61-66, 2019. PMID: 30721697.

185. Charkoftaki G; Wang Y; McAndrews M; Bruford EA; Thompson DC; **Vasiliou V**, Nebert DW. Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an “evolutionary bloom”. **Hum Genomics** 13:11, 2019. PMID: 30782214.
186. Chen Y, Golla S, Garcia-Milan R, Thompson DC, Gonzalez FJ, **Vasiliou V**. Hepatic metabolic adaptation in a murine model of glutathione deficiency. **Chemico-Biol Interact** 303: 1-6, 2019. PMID: 30794799.
187. Charkoftaki G, Thompson DC, Garcia-Milian R, Golla JP, Lam TK, Jasper Engel J, **Vasiliou V**. Integrated multi-omics approach reveals a role of ALDH1A1 in lipid metabolism in human colon cancer cells. **Chemico-Biol Interact** 304: 88-96, 2019 PMID: 30851239.
188. Pantouris G, Dioletis E, Chen Y, Thompson DC, **Vasiliou V**, Lolis EJ. Expression, purification and crystallization of the novel *Xenopus tropicalis* ALDH16B1, a homologue of human ALDH16A1. **Chemico-Biol Interact** 304: 168-172, 2019. PMID: 30894314.
189. Kant S, Davuluri G, Alchirazi K, Heit C, Kumar A, Gangadhariah M, McMullen M, Nagy N, **Vasiliou V**, Marini AM, Weiner D, Dasarathy S. Ethanol sensitizes skeletal muscle to ammonia-induced molecular perturbations. **J Biol Chem** 294: 7231-7244; 2019. PMID: 30872403.
190. Alofe O, Kisanga E, Inayat-Hussain S, Fukumura M, Garcia-Milian R, Perera L, **Vasiliou V**, Whirledge S. Determining the endocrine disruption potential of industrial chemicals using an integrative approach: Public databases, in vitro exposure, and modeling receptor interactions. **Environ International** 131: 104969, 2019. PMID: 31310931.
191. Godri Pollitt KJ, Kim J-H, Peccia J, Elimelech M, Zhang Y, Charkoftakia G, Hodges B, Zucker I, Huang H, Deizel NC, Murphy K, Ishii M, Johnson CH, Boissevain A, O’Keefe E, Anastas P, Orlicky D, Thompson DC, Vasiliou, V. 1,4-Dioxane as an emerging water contaminant – State of the science and evaluation of research needs. **Sci Total Environ** 690: 853-866, 2019. PMID: 31302550.
192. Chen Y, Manna SK, Golla S, Krausz KW, Cai Y, Garcia-Milian R, Chakraborty T, Chakraborty J, Chatterjee R, Thompson DC, Gonzalez FJ, Vasillou V. Glutathione deficiency-elicited reprogramming of hepatic metabolism protects against alcohol-induced steatosis. **Free Radic Med Biol** 143: 127-139, 2019. PMID: 31351176.
193. Sun Y, Mironova V, Chen Y, Lundh E, Zhang Q, Cai Y, **Vasiliou V**, Zhang Y, Garcia-Milian R, Khan S, Johnson C. Molecular pathway analysis indicates a distinct metabolic phenotype in women with right-sided colon cancer. **Transl Oncol** 13: 42-56, 2020,. PMID: 31760268.
194. Liu P, Ioannidis JPAI, Ross JS, Dhruva SS, Luxkaranayagam AT, **Vasiliou V**, Wallach JD. Age-treatment subgroup analyses in Cochrane intervention reviews: A meta-epidemiological study. **BMC Medicine** 17: 188, 2019. PMID: 31639007.
195. Liu P, Ross JS, Ioannidis JP, Dhruva SS, **Vasiliou V**, Wallach JD. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. **Clin Trials** 17: 231-234, 2019. PMID: 31709809.
196. Thompson B, Katsanis N, Apostolopoulos N, Thompson DC, Nebert DW, **Vasiliou V**. Genetics and functions of the retinoic acid pathway, with special emphasis on the eye. **Hum Genomics**, 2019 13(1): 61, 2019. PMID: 31796115, PMCID: PMC6892198.
197. Kandyliari K, Mallouchos A, Papandroulakis A, Golla JP, Sakellari K, Karavoltos S, **Vasiliou V**, Kapsokefalou M. Nutrient composition, fatty acid and protein profile of fish by-products. **Foods** 9(2): 190, 2020. PMID: 32075005, PMCID: PMC7074476.
198. Chu L, Ioannidis JPA, Egilman AC, **Vasiliou V**, Ross JS, Wallach JD. Vibration of effects in epidemiological studies of alcohol consumption and breast cancer risk. **Int J Epidemiol** 49: 608-

- 618, 2020. PMID: 31967637, PMCID: PMC7266551.
199. Kurniawan H, Franchina DG, Grusdat M, Nonnenmacher Y, Bonetti L, Guerra L, Hunewald O, Dostert C, Binsfeld C, Duncan G, Farinelle S, Haight J, Gupta D, Taskesen R, Halder R, Ying Chen Y, Ollert M, Wilmes P, **Vasiliou V**, Harris I, Knobbe-Thomsen CB, Mak TW, Lohoff M, Hiller K, Brenner D. Glutathione restricts serine metabolism to preserve regulatory T cell functionality. **Cell Metabolism** 31(5): 920-936.e7, 2020. PMID: 32213345, PMCID: PMC7265172.
 200. Koelmel JP, Li X, Stow SM, Sartain MJ, Murali A, Kemperman R, Tsugawa H, Takahashi M, **Vasiliou V**, Bowden JA, Yost RA, Garrett TJ, Kitagawa N. Lipid annotator: Towards accurate annotation in non-targeted liquid chromatography high-resolution tandem mass spectrometry (LC-HRMS/MS) lipidomics using a rapid and user-friendly software. **Metabolites** 10: 101, 2020. PMID: 32178227, PMCID: PMC7142889.
 201. Wallach JD, Serghiou S, Chu L, Egilman AC, **Vasiliou V**, Ross JS, Ioannidis JPA. Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease. **BMC Med Res Methodol** 20: 64, 2020. PMID: 32171256, PMCID: PMC7071725.
 202. Koelmel JP, Napolitano MP, Ulmer CZ, **Vasiliou V**, Garrett TJ, Yost RA, Prasad MNV, Godri Pollitt KJ, Bowden JA. Environmental lipidomics: Understanding the response of organisms and ecosystems to a changing world. **Metabolomics** 16: 56, 2020. PMID: 32307636.
 203. Godri Pollitt KJ, Peccia J, Ko AI, Kaminski N, Dela Cruz CS, Nebert DW, Reichardt JKV, Thompson DC, **Vasiliou V**. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission, **Hum Genomics** 14(1): 17, 2020. PMID: 32398162, PMCID: PMC7214856.
 204. McMahan RH, Afshar M, Amedee AM, Bishehsari F, Carr RM, Coleman LG, Herrnreiter CJ, Lewis SL, Mandrekar P, McCullough RL, Morris NL, **Vasiliou V**, Wang HJ, Yeligar SM, Choudhryd MA, Kovacs EJ. Summary of the 2019 Alcohol and Immunology Research Interest Group (AIRIG) meeting: Alcohol-mediated mechanisms of multiple organ injury. **Alcohol** 87: 89-95, 2020. PMID: 32353591.
 205. Comess S, Akbay A, Vasiliou M, Ronald N, Hines RN, Joppa L, **Vasiliou V**, Kleinstreuer N. Bringing big data to bear in environmental public health: Challenges and recommendations. **Front Artif Intell** 3: 3, 2020. PMID: 33184612.
 206. Luo J, Wu W, Zhang P, Chen X, Feng Y, Ma N, Yang H, Wang Y, Li M, Xie B, Guo P, Liew Z, Deziel NC, **Vasiliou V**, Xiaoming Shi X, Wang S, Zhang Y. Zinc levels and birth weight in pregnant women with gestational diabetes mellitus: a matched cohort study in China. **J Clin Endocrinol Metab** 105(7). pii: dgaa171, 2020. PMID: 32285111.
 207. Godri Pollitt KJ, Peccia J, Ko AI, Kaminski N, Dela Cruz CS, Nebert DW, Reichardt JKV, Thompson DC, **Vasiliou V**. COVID-19 vulnerability: The potential impact of genetic susceptibility and airborne transmission. **Hum Genomics** 14(1):17, 2020. PMID: 32398162, PMCID: PMC7214856.
 208. Mehrian-Shai R, Novelli G, **Vasiliou V**, Watt J, Reichardt JKV. Genomics of COVID-19: molecular mechanisms going from susceptibility to severity of the disease. **Hum Genomics** 14: 22, 2020; PMCID: PMC7283035.
 209. Aksenov A, Laponogov I, Zhang Z, Doran S, Belluomo I, Veselkov D, Bittremieux W, Nothias LF, Nothias-Esposito M, amp, eacutelissa, Maloney KN, Misra BB, Melnik AV, Jones KL, Dorrestein K, Panitchpakdi M, Ernst M, van der Hooft JJJ, Gonzalez M, Carazzone C, Am, amp, eacutezquita A, Callewaert C, Morton J, Quinn RA, Bouslimani A, Albarracin Orio A, Petras D, Smania AM, Couvillion SP, Burnet MC, Nicora CD, Zink E, Metz TO, Artaev V, Humston-Fulmer

- E, Gregor R, Meijler MM, Mizrahi I, Eyal S, Anderson B, Dutton RJ, Lugan R, Le Boulch P, Guillon Y, Prevost S, Poirier A, Dervilly G, Le Bizec B, Fait A, Sikron N, Song C, Gashu K, Coras R, Guma M, Manasson J, Scher JU, Barupal DK, Alseekh S, Fernie A, Fernie AR, Mirnezami R, **Vasiliou V**, Schmid R, Borisov RS, Kulikova LN, Knight R, Wang M, Hanna G, Dorrestein PC, Veselkov K. (2020). Auto-deconvolution and molecular networking of gas chromatography-mass spectrometry data. **Nat Biotechnol** 39: 169-173, 2021. PMID: 33169034, PMCID: PMC7971188.
210. Koelmel JP, Paige M, Aristizabal-Henao JJ, Robey NM, Nason S, Stelben P, Li Y, Kroeger NM, Savvaides T, **Vasiliou V**, Rostkowski P, Garrett TJ, Lin E, Deigl C, Jobst K, Townsend TG, Krystal J, Godri Pollitt KJ, Bowden JA. Towards comprehensive PFAS annotation using FluoroMatch Software and Intelligent LC-HRMS/MS acquisition methods. **Anal Chem** 92: 11186-11194, 2020. PMID: 32806901.
211. Thompson B, Davidson DA, Wei Liu W, Nebert DW, Bruford EA, Zhao T, Dermitzakis ET, David C. Thompson DC, **Vasiliou V**. Overview of PAX gene family and analysis of human tissue-specific variant expression. **Hum Genetics** 140: 381-400, 2021. PMID: 32728807.
212. Golla JP, Kandyliari A, Tan WY, Chen Y, Orlicky DJ, Thompson DC, Shah YM, **Vasiliou V**. Interplay between APC and ALDH1B1 in a newly developed mouse model of colorectal cancer. **Chemico-Biol Interact** 331: 109274, 2020. PMID: 33007288.
213. Burman A, Garcia-Milian R, Wood M, DeWitt NA, **Vasiliou V**, Guller S, Abrahams VM, Whirlledge S. Acetaminophen attenuates invasion and alters the expression of extracellular matrix enzymes and vascular factors in human first trimester trophoblast cells. **Placenta** 104: 146-160, 2020. PMID: 33348283.
214. Novelli G, Biancolella M, Mehrian-Shai R, Erickson C, Godri Pollitt K, **Vasiliou V**, Watt J, Reichardt KV. COVID-19 Update: The first 6 Months of the pandemic. **Hum Genomics**, 14(1): 48, 2020. PMID: 33357238.
215. Deng W, Jin L, Zhuo H, **Vasiliou V**, Zhang Y. Alcohol consumption and risk of stomach cancer: A meta-analysis. **Chem Biol Interact**, 336: 109365, 2021. PMID: 33412155.
216. Laponogov I, Gonzalez G, Shepherd M, Qureshi A, Veselkov D, Charkoftaki G, **Vasiliou V**, Youssef J, Mirnezami R, Bronstein B, Veselkov K. Network machine learning maps phytochemically-rich "Hyperfoods" to fight COVID-19. **Hum Genomics** 15(1):1, 2021, PMID: 33386081.
217. Jain D, Torres R, Celli R, Koelmel J, Charkoftaki G, **Vasiliou V**. Evolution of the liver biopsy and its future. **Transl Gastroenterol Hepatol** 6: 20, 2021. PMID: 33824924.
218. Novelli G, Biancolella M, Mehrian-Shai R, Colona VL, Brito AF, Grubaugh ND, **Vasiliou V**, Luzzatto L, Reichardt JKV. COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. **Hum Genomics** 15(1): 27, 2021. PMID: 33966626.
219. Charkoftaki G, Golla JP, Santos-Neto A, Orlicky DJ, Garcia-Milian R, Chen Y, Rattray NJW, Cai Y, Wang Y, Shern CT, Mironova V, Wang Y, Johnson CH, Thompson DC, **Vasiliou V**. Identification of dose-dependent DNA damage and repair responses from subchronic exposure to 1,4-dioxane in mice using a systems analysis approach. **Toxicol Sci** 183(2): 338-351, 2021. PMID: 33693819.
220. Furnary T, Garcia-Milian R, Liew Z, Whirlledge S, **Vasiliou V**. In silico exploration of the potential role of acetaminophen and pesticides in the etiology of autism spectrum disorder. **Toxics** 9(5): 97, 2021. PMID: 33925648.
221. Hagstrom AL, Anastas P, Boissevain A, Borrel A, Deziel NC, Fenton SE, Fields C, Fortner JD, Franceschi-Hofmann N, Frigon R, Jin L, Kim JH, Kleinstreuer NC, Koelmel J, Lei Y, Liew Z, Ma X,

- Mathieu L, Nason SL, Organtini K, Oulhote Y, Pociu S, Godri Pollitt KJ, Saiers J, Thompson DC, Toal B, Weiner EJ, Whirledge S, Zhang Y, **Vasiliou V**. Yale School of Public Health Symposium: An overview of the challenges and opportunities associated with per- and polyfluoroalkyl substances (PFAS). **Sci Total Environ** 778: 146192, 2021. PMID: 33714836.
222. Jin L, Godri Pollitt KJ, Liew Z, Rosen Vollmar AK, **Vasiliou V**, Johnson CH, Zhang Y. Use of untargeted metabolomics to explore the air pollution related disease continuum. **Curr Environ Health Rep** 8(1): 7-22, 2021. PMID: 33420964.
223. Maimaitiyiming Y, Wang QQ, Yang C, Ogra Y, Lou Y, Smith CA, Hussain L, Shao LM, Lin J, Liu J, Wang L, Zhu Y, Lou H, Huang Y, Li X, Chang K-J, Chen H, Li H, Huang Y, Tse E, Sun J, Bu N, Chiou S-H, Zhang YF, Hua HY, Ma LY, Huang P, Ge MH, Cao F-L, Cheng X, Sun H, Zhou J, **Vasiliou V**, Xu P, Jin J, Bjorklund M, Zhu H, Hsu C-H, Naranmandura H. Hyperthermia selectively destabilizes fusion oncoproteins. **Blood Cancer Discov** 2(4): 388-401, 2021. PMID: 34661159, PMCID: PMC8513904.
224. Tang S, Li T, Fang J, Chen R, Cha Y, Wang Y, Zhu M, Zhang Y, Chen Y, Du Y, Yu T, Thompson DC, Godri Pollitt KJ, **Vasiliou V**, Jig JS, Kan H, Zhang J, Shi X. The Exposome in practice: Design and rationale for the study of biomarkers of air pollutants exposure in Chinese aged 60-69 (China BAPE Study). **Environ Int** 157: 106866. 2021. PMID: 34525388.
225. Thompson B, Chen Y, Davidson EA, Garcia-Milian R, Golla JP, Apostolopoulos N, Orlicky DJ, Schey K, Thompson DC, **Vasiliou V**. Impaired GSH biosynthesis disrupts eye development and PAX6 function. **Ocul Surf** 22: 190-203, 2021. PMID: 34425299.
226. Koelmel JP, Aristizabal-Henao J, Ni Z, Fedorova M, Kato S, Otoki Y, Nakagawa K, Lin, E; Godri Pollitt, K; **Vasiliou V**, Guingab J, Garrett TJ, Williams T; Bowden J, A novel technique for redox lipidomics using mass spectrometry: application on vegetable oils used to fry potatoes. **J Am Soc Mass Spectrom** 32: 1798-1809, 2021. PMID: 34096708.
227. Johnson CH, Golla JP, Dioletis E, Singh S, Ishii M, Georgia Charkoftaki G, David C. Thompson DC, **Vasiliou V**. Molecular mechanisms of alcohol-induced colorectal carcinogenesis. **Cancers** 13: 4404, 2021. PMID: 34503214.
228. Chen Y, Wang Y, Charkoftaki G, Orlicky DJ, Davidson E, Wan F, Ginsberg G, David C. Thompson DC, **Vasiliou V**. Oxidative stress and genotoxicity in 1,4-dioxane liver toxicity as evidenced in a mouse model of glutathione deficiency. **Sci Total Environ** 806(Pt 2):150703, 2022. doi: 10.1016/j.scitotenv. 150703. PMID: 34600989.
229. Neumann N, Thompson DC, **Vasiliou V**. AMPK activators for the prevention of neurodegenerative diseases. **Expert Opin Drug Metab & Toxicol** 17(10): 1199-1210, 2021. PMID: 34632898.
230. Galani A, Aalizadeh R, Kostakis M, Markou A, Alygizakis N, Lytras T, Adamopoulos PG, Peccia J, Thompson DC, Kontou K, Karagiannidis A, Evi S. Lianidou ES, Avgeris M, Paraskevis D, Tsiodras S, Scorilas A, **Vasiliou V**, Dimopoulos M-A, Thomaidis NS. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. **Sci Total Environ** 804: 150151, 2022. doi: 10.1016/j.scitotenv.2021.150151. PMID: 34623953, PMCID: PMC8421077.
231. Koelmel J, Wan T, Yang L, Bowden J, Ahmadireskety A, Patt A, Orlicky D, Mathe E, Kroeger N, Thompson DC, Cochran J, Golla J, Kandyliari K, Chen Y, Charkoftaki G, Guingab-Cagmat J, Tsugawa H, Arora A, Veselkov, K; Kato S, Otoki Y, Nakagawa K, Yost R, Garrett T, **Vasiliou V**. Lipidomics and redox lipidomics indicate early-stage alcohol-induced liver damage. **Hepatol Commun** 6: 513-525, 2022. PMID: 34811964, PMCID: PMC8870008.
232. Luo J, Ramlau-Hansen CH, Kesmodel US, Xiao J, **Vasiliou V**, Deziel NC, Zhang Y, Olsen J, Liew Z. Prenatal exposure to perfluoroalkyl substances and facial features at age 5: a study from the

- Danish national birth cohort, **Environ Health Perspect** 130(1): 17006, 2021. PMID: 35080464.
233. Denys A, Pedersen K, Watt J, Norman A, Osborn A, Chen J-R, Maimone C, **Vasiliou V**, Ronis M. Binge ethanol exposure in mice represses expression of genes involved in osteoblast function and induces expression of genes involved in osteoclast differentiation throughout the skeleton. **Tox Sci** 185(2): 232-245, 2022. PMID: 34755883, PMCID: PMC9019842.
234. Gapstur SM, Bandera EV, Jernigan DH, LoConte NK, Southwell BG, **Vasiliou V**, Brewster AM, Naimi TS, Scherr CL, Shield KD. Alcohol and cancer: existing knowledge and evidence gaps across the cancer continuum. **Cancer Epidemiol Biomarkers Prev** 31(1): 5-10, 2021. PMID: 34728469, PMCID: PMC8755600.
235. Franchina D, Kurniawan H, Guerra L, Bonetti L, Soriano-Baguet L, Ewen A, Grusdat M, Kobayashi T, Binsfeld C, Farinelle S, Minafra A, Vandamme N, Carpentier A, Kleine Borgmann F, Chen Y, **Vasiliou V**, Kleinewietfeld M; Michel Mittelbronn M, Philipp A, Lang PA, Brenner D. Glutathione-dependent redox balance defines the distinct metabolic properties of Follicular and Marginal Zone B cells. **Nat Commun** 13(1): 1789, 2022. PMID: 35379825, PMCID: PMC8980022.
236. Ho M, Thompson B, Fisk JN, Nebert DW, Bruford EA, **Vasiliou V**, Bunick CG. Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders. **Hum Genomics** 16(1):1, 2022. PMID: 34991727, PMCID: PMC8733776.
237. Thompson B, Davidson EA, Chen Y, Orlicky DJ, Thompson DC, **Vasiliou V**. ROS in lens cells triggers and inflammatory response and immune surveillance of ocular tissues. **Chemico-Biol Interact** 355: 109804, 2022. PMID: 35123994.
238. Rock S, Costello E, Stratakis N, Eckel S, Walker DI, Valvi D, Cserbik D, Jenkins T, Stavra A, Xanthakos SA, Kohli R, Sisley S, **Vasiliou V**, Merrill MA, Hugo Rosen H, Conti C, McConnell R, Chatzi L. Exposure to per- and polyfluoroalkyl substances and liver injury: a systematic review and meta-analysis, **Environ Health Perspect**, 130(4): 46001, 2022. PMID: 35475652.
239. Guo P, Furnary T, **Vasiliou V**, Yan Q, Nyhan K, Jones DP, Johnson CH, Liew Z. Non-targeted metabolomics and associations with per- and polyfluoroalkyl substances (PFAS) exposure in humans: A scoping review, **Environ Intern** 162: 107159, 2022. PMID: 35231839.
240. Charkoftaki G, Tan WY, Berrios-Carcamo P, Orlicky DJ, Golla JP, Garcia-Milian R, Aalizadeh R, Thomaidis NS, Thompson DC, **Vasiliou V**. Liver metabolomics identifies bile acid profile changes at early stages of alcoholic liver disease in mice. **Chem Biol Interact** 360: 109931, 2022. PMID: 35429548, PMCID: PMC9364420.
241. Wang Y, Charkoftaki G, Davidson E, Orlicky DJ, Tanguay RL, Thompson DC, **Vasiliou V**, Chen Y. Oxidative stress, glutathione and CYP2E1 in 1,4-dioxane liver cytotoxicity and genotoxicity: Insights from animal models, **Curr Opin Environ Sci Health** 29 <https://doi.org/10.1016/j.coesh.2022.100389>.
242. Wang Y, Garcia-Milian R, Thompson DC, Charkoftaki G, Lam TM, **Vasiliou V**. Proteomic profiling of human colon cancer cells reveals a potential regulatory role of aldehyde dehydrogenases in cell proliferation and energy metabolism. **Chemico-Biol Interact**, 368:110175, 2022. doi: 10.1016/j.cbi.2022.110175. Online ahead of print. PMID: 36162455.
243. Zuccaro P, Thompson DC, Boer J, Watterson A, Wang Q, Tang S, Shi X, Llompert M, Nuno Ratola N, **Vasiliou V**. Artificial turf and crumb rubber infill: An international policy review concerning the current state of regulations, **Environ Chall**, Vol 7, December 2022. PMID: 36644410; PMCID:PMC9838222. <https://doi.org/10.1016/j.envc.2022.100620>.
244. Dornburg A, Mallik R, Wang Z, Bernal MA, Thompson B, Bruford EA, Nebert DW, **Vasiliou V**,

- Yohe LR, Yoder JA, Townsend JP. Placing human gene families into their evolutionary context, **Hum Genomics** 16(1): 56, 2022. doi: 10.1186/s40246-022-00429-5. PMID: 36369063, PMCID: PMC9652883.
245. Ginsberg G, Chen Y, **Vasiliou V**. Mechanistic considerations in 1,4-dioxane cancer risk assessment, **Curr Opin Environ Sci Health**, December 2022, <https://doi.org/10.1016/j.coesh.2022.100407>.
246. Zuccaro P, Licato J, Davidson E, Thompson DC, **Vasiliou V**. Assessing extraction-analysis methodology to detect fluorotelomer alcohols (FTOH), a class of perfluoroalkyl and polyfluoroalkyl substances (PFAS), in artificial turf fibers and crumb rubber infill. **Case Stud. Chem. Environ. Eng.** 2023, <https://doi.org/10.1016/j.cscee.2022.100280>.
247. Bellia GRM, Bilott RA, Sun N, Thompson D, **Vasiliou V**. Use of clinical chemistry health outcomes and PFAS chain length to predict 28-day rodent oral toxicity. **Toxicol Mech Methods.** 2022 Nov 29:1-10. doi:10.1080/15376516.2022.2150591. Online ahead of print. PMID: 36446747.
248. Hang Zhou H, **Vasiliou V**. Alcohol use and use disorder and cancer risk: Perspective on causal inference. **Complex Psychiatry** 8(1-2): 9-12, 2022. PMID: 36601413 PMCID: PMC9669948.

Preprints

249. Aksenov A, Laponogov I, Zhang Z, Doran S, Belluomo I, Veselkov D, Bittremieux W, Nothias LF, Nothias-Esposito M, Maloney KN, Misra BB, Melnik AV, Jones KL, Dorrestein K, Panitchpakdi M, Ernst M, van der Hooft JJJ, Gonzalez M, Carazzone C, Callewaert C, Morton J, Quinn RA, Bouslimani A, Albarracin Orio A, Petras D, Smania AM, Couvillion SP, Burnet MC, Nicora CD, Zink E, Metz TO, Artaev V, Humston-Fulmer E, Gregor R, Meijler MM, Mizrahi I, Eyal S, Anderson B, Dutton RJ, Lugan R, Le Boulch P, Guitton Y, Prevost S, Poirier A, Dervilly G, Le Bizec B, Fait A, Sikron N, Song C, Gashu K, Coras R, Guma M, Manasson J, Scher JU, Barupal DK, Alseekh S, Fernie A, Fernie AR, Mirnezami R, **Vasiliou V**, Schmid R, Borisov RS, Kulikova LN, Knight R, Wang M, Hanna G, Dorrestein PC, Veselkov K. Algorithmic learning for auto-deconvolution of GC-MS data to enable molecular networking within GNPS. **bioRxiv** 2020.01.13.905091. Available from: <https://t.co/MRc9nWISQD>.
250. Thompson B, Chen Y, Philippe J, Anderson A, Golla J, Davidson E, Apostolopoulos N, Schey K, Katsanis N, Orlicky D, Thompson D, **Vasiliou V**. Gclc deletion in surface-ectoderm tissues induces microphthalmia. **bioRxiv** 700591. Available from: <https://doi.org/10.1101/700591>.
251. Charkoftaki G, Golla JP, Santos-Neto AJ, Orlicky DJ, Garcia-Milian R, Chen Y, Rattray NJW, Cai Y, Wang Y, Shern CT, Mironova V, Wang Y, Johnson CH, Thompson DC, **Vasiliou V**. Novel insights into the mode of action of 1,4-dioxane using a systems screening approach. **bioRxiv** 2020.12.27.424470. Available from: <https://doi.org/10.1101/2020.12.27.424470>.
252. Asantewaa G, Tuttle ET, Ward NP, Kang YP, Kim Y, Kavanagh ME, Girnius N, Chen Y, Duncan R, Rodriguez K, Hecht F, Zocchi M, Smorodintsev-Schiller L, Scales TQ, Taylor K, Alimohammadi F, Sechrist ZR, Agostini-Vulj D, Schafer XL, Chang H, Smith Z, O'Connor TN, Whelan S, Selfors LM, Crowdis J, Gray GK, Bronson RT, Brenner D, Rufini A, Dirksen RT, Hezel AF, Huber AR, Munger J, Cravatt BF, **Vasiliou V**, Cole CL, DeNicola GM, Harris IS. Glutathione supports lipid abundance *in vivo*. **bioRxiv** 2023.02.10.524960; doi: <https://doi.org/10.1101/2023.02.10.524960>.

Book Chapters

1. **Vasiliou V**, Athanasiou K, Marselos M. The use of ALDH induction as a carcinogenic risk marker in comparison with a typical *in vitro* system. In: *Biologically Based Methods for Cancer Risk*

- Assessment* (C.C. Travis Ed), New York: Plenum Press, pp. 231-240, 1988.
2. Pappas P, **Vasiliou V**, Karageorgou M, Marselos M. Changes on the inducibility of a hepatic aldehyde dehydrogenase after treatment with a glutathione depletor. In: *Alcoholism: A Molecular perspective*. (T.N. Palmer Ed). Plenum Press, New York, pp. 115-120, 1991.
 3. Sophos NA, Black W, **Vasiliou V**. An update of the ALDH gene superfamily. In: *Enzymology and Molecular Biology of Carbonyl Metabolism*" (H. Weiner, R. Lindahl, E. Maser, B.V. Plapp Eds), Purdue University Press, pp. 3-7, 2005.
 4. Estey T, Lassen N, Pappa A, Vasiliou. ALDH3A1 is a multifunctional protein that protects against oxidative damage. In "Enzymology and Molecular Biology of Carbonyl Metabolism" (H. Weiner, R. Lindahl, E. Maser, B.V. Plapp Eds), Purdue University Press, pp. 50-55, 2005.
 5. Deitrich RA, Petersen D, **Vasiliou V**. Removal of acetaldehyde from the body. *Novartis Found Symp.* **285**: 23-40, 2007, PMID: 17590985.
 6. Marchitti SA, Bateman BJ, Petrash JM, **Vasiliou V**. Mouse models of the cornea and lens: understanding ocular disease. In: *Animal Models for Eye Research* (P.A. Tsonis Ed.). Elsevier, pp. 148-165, 2008.
 7. **Vasiliou V**, Petersen DR. Aldehyde dehydrogenases. In *Comprehensive Toxicology* (C. McQueen Ed.). Elsevier, ISBN: 978-0-08-046884-6, 2010.
 8. Zakhari S, Radaeva S, **Vasiliou V**. Hepatic and extrahepatic malignancies in alcoholic liver disease. In *Alcoholic and Non-Alcoholic Fatty Liver Disease*, (N. Chalasani, G. Szabo eds.), DOI 10.1007/978-3-319-20538-0_13, Springer International Publishing, Switzerland 2016.
 9. **Vasiliou V**, Thompson DC, Petersen DR. Aldehyde Dehydrogenases, In: *Comprehensive Toxicology, Third Edition* (C.A. McQueen Ed.) Oxford: Elsevier Ltd., Vol. 10, pp. 146-163, 2018.
 10. **Vasiliou V**, Akbay A. Genomics as a driving force for climate change response and community health. In: *A Better Planet: Forty Big Ideas for a Sustainable Future* (D. Esty Ed), ISBN: 9780300246247, Yale University Press, pp.105-111, 2019.

Books

- Alcohol and Cancer* (S. Zakhari S, B. Gao B, V. Vasiliou Eds). Springer 2011, ISBN 978-1-4614-0039-4.
- Biological Basis of Alcohol-Induced Cancer* (V. Vasiliou, S. Zakhari, H.K. Seitz, J.B. Hoek Eds), *Adv Exp Med Biol*, **815**, 2015, Springer, ISBN: 978-3-319-09613-1.
- Alcohol and Cancer - Proceedings of the Third International Conference* (V. Vasiliou, S. Zakhari, H.K. Seitz, L. Mishra Eds) *Adv Exp Med Biol* 1032, Springer, Print ISBN 978-3-319-98787-3; Online ISBN 978-3-319-98788-0.

Editorials

1. **Vasiliou V**. *Human Genomics* **3**: 1-2, 2008. PMID: PMC3525182.
2. **Vasiliou V**. *Human Genomics* **3**: 101-102, 2009, PMID: PMC3525275.
3. **Vasiliou V**. *Human Genomics* **3**: 211-212, 2009, PMID: PMC3500191.
4. **Vasiliou V**. *Human Genomics* **4**: 1, 2009, PMID: PMC3500184.
5. **Vasiliou V**. *Human Genomics* **5**: 137, 2011, PMID: PMC3500168.
6. **Vasiliou V**. *Human Genomics* **5**: 419, 2011, PMID: PMC3525968.
7. **Vasiliou V**, Nebert DW, A new home for Human Genomics. *Human Genomics* **6**:1, 2012, PMID: PMC3437565.

8. **Vasiliou V**, Veselkov K, Bruford E, Reichardt JKV. Standardized nomenclature and open science in Human Genomics. *Human Genomics* **15**: 13, 2021, PMID: 33612096.
9. Colona VL, **Vasiliou V**, Watt J, Novelli G, Reichardt JKV. Update on human genetic susceptibility to COVID-19: susceptibility to virus and response. *Human Genomics* **15**: 57, 2021, PMID: 34429158
10. Petrash JM, **Vasiliou V**. Editorial for carbonyl metabolism. *Chem Biol Interact* **363**: 110006, PMID: 35662544.

IN THE NEWS

- [CU research: Enzyme discovered that could detect colon cancer earlier](#). The Denver Post, September 5, 2011.
- [Alcohol and Cancer: A Devastating Bond \(Interview in Greek\)](#), Creta TV, Jun 2, 2015.
- [The Threat of Lead](#), Yale School of Public Health, *February 02, 2016*.
- [Yale Research Provides Insights into Alcoholic Liver Disease](#), Yale School of Public Health, *April 8, 2016*.
- [YSPH Volunteers Help Collect Trash on Branford, East Haven Beaches](#), Yale School of Public Health, *September 19, 2016*.
- [YSPH To Host Advance Screening of Risky Drinking, Documentary on the Dangers of Alcohol Abuse](#), Yale School of Public Health, *November 14, 2016*.
- [HBO Documentary on Alcoholism Previewed at Yale School of Public Health](#), Yale School of Public Health, *November 22, 2016*.
- [Yale prof raises concerns about potential health hazards of recreational marijuana](#), New Haven Register, *January 14, 2017*.
- [Soccer players' cancers ignite debate over turf safety](#), CNN, *January 27, 2017*.
- [Dozens of soccer players at the same university diagnosed with CANCER - after playing on 'contaminated' field](#), DailyMail.com, *January 27, 2017*.
- [The Risks of Lifetime Environmental Exposures Explored at YSPH Model](#), Yale School of Public Health, *April 24, 2017*.
- [Scholars Take a Deep Dive into Tissue Imaging Mass Spectrometry](#), Yale School of Public Health, *October 24, 2017*.
- [190 Substances Indicate Carcinogenic Potential](#), So Foot.com, *December 8, 2017*.
- [Building Research Networks and Friendships, Fulbright Fellow Looks Forward to Future Collaborations](#), Yale School of Public Health, *December 14, 2017*.
- [Experts Convene to Discuss Improving Reproducible Research Practices for Schools of Public Health](#), Yale School of Public Health, Yale School of Public Health, *April 23, 2018*.
- [Yale to Host Conference on Olive Oil, Plans to Establish Research Center](#), Olive Oil Times, *September 17, 2018*.
- [Olive oil's health benefits explored at Yale School of Public Health symposium](#), Yale School of Public Health, *October 10, 2018*.
- [Cutting-edge Instrument Expected to Foster Novel Scientific Insights](#), Yale School of Public Health, *December 11, 2018*.
- [Turf field to be installed in Yale Bowl](#), Yale Daily News, *January 25, 2019*.

- [YSPH Convenes Experts to Examine Alcohol's Role in Cancer](#), Yale School of Public, *April 24, 2019*.
- [If Your Olive Oil Tastes Like This, It Could Help Fight Cancer Cells](#), HuffPost.com, *August 28, 2019*.
- [Undergraduate Students Spend Summer Learning About Environmental Health Sciences](#), Yale School of Public Health, *September 10, 2019*.
- [CT moves to reduce PFAS usage](#), Yale Daily News, *November 8, 2019*.
- [Jeff Jacobs: Time will tell if FieldTurf is best for Yale Bowl](#), The MiddletownPress, *August 16, 2019*.
- [Congresswoman DeLauro Calls for Ban of PFAS in Food Containers](#), Yale School of Public Health, *October 09, 2019*.
- [YSPH International Olive Oil and Health Symposium to be Held in Legendary City of Delphi](#), School of Public Health, *October 22, 2019*.
- [Prying into the Origins of Disease, Experts Gather at YSPH for Scientific Imaging Symposium](#), Yale School of Public Health, *November 25, 2019*.
- [Yale Professors on a Mission to Spread the Word On Olive Oil](#), WSHU Public Radio, *November 27, 2019*.
- [Threat of Toxic Chemicals Draws Scores of Experts to Yale School of Public Health](#), Yale School of Public Health, *December 17, 2019*.
- [PFAS and Health: Troublesome, Ubiquitous Chemicals to be Examined at YSPH Symposium](#), Yale School of Public Health, *December 12, 2019*.
- [Yale Researchers Convene Olive Oil Symposium in Delphi](#), Greek Reporter, *December 19, 2019*.
- [The EPA Finally Plans to Regulate Toxic, Widespread 'Forever Chemicals'](#), Very Well Health, *December 01, 2021*.
- [Yale partners with the National Kapodistrian University of Athens to advance environmental science and public health](#), Yale and the World, *October 18, 2021*.
- [Distinguished New Faculty Join YSPH's Department of Environmental Health Sciences](#), Yale School of Public Health, *October 01, 2021*.
- [Study finds raw wastewater 'leading indicator' of future COVID-19 outbreaks](#), Medicalxpress, *September 8, 2021*.
- [Yale University Researches Health Benefits of Organic Olives from Greece](#), The Greek Reporter, *October 16, 2021*.
- [Yale Symposium to Explore the Health Benefits of Extra Virgin Olive Oil, Morocco Gold](#), *October 17, 2021*.
- [Olive Oil's Many Health Benefits to be Explored in Yale Symposium in Spain](#), Yale School of Public Health, *October 07, 2021*.
- [USC study links PFAS to liver damage; YSPH scientist contributed to research](#), Yale School of Public Health, *April 27, 2022*.
- [From drinking water to dust: Yale experts share insights on future of hazardous 'forever' chemicals](#), Yale Daily News, *August 30, 2022*.
- [Yale experts look toward olive oil in the fight against Alzheimer's, cancer and more](#), Yale Daily News, *September 12, 2022*.
- [The Vatican Wants to Know: What is the role of olive trees in supporting a healthy, sustainable, and just world?](#) North American Olive Oil Association, *2022*.

- Yale to study mass casualty prevention strategies through Italian partnership, Yale Daily News, *September 20, 2022*.
- Olive Oil's Many Human and Planetary Health Benefits Discussed at 4th Annual International Yale Symposium, Yale School of Public Health, *September 22, 2022*.
- Yale launches Superfund Center to address drinking water contamination, Yale Daily News, *October 17, 2022*.
- Yale-NKUA partnership featured at 2022 Pharos Summit in Greece, Yale and the World, *December 12, 2022*.
- Famed "forever chemicals" lawyer Robert Bilott talks PFAS and policy at Yale, Yale Daily News, *February 26, 2023*.
- Litigator and environmental advocate Rob Bilott discusses threat of PFAS 'forever chemicals', Yale School of Public Health, *February 28, 2023*.
- The proposed Institute Yale Olive Sciences and Health Institute, Olive Oil Portal.
- Ohio Train Derailment: A Plan of Action for Public Health, Yale School of Public Health, *February 23, 2023*.